<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="systematic-review" dtd-version="1.2" xml:lang="en">
    <front>
        <journal-meta>
            <journal-id journal-id-type="pmc">F1000Research</journal-id>
            <journal-title-group>
                <journal-title>F1000Research</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2046-1402</issn>
            <publisher>
                <publisher-name>F1000 Research Limited</publisher-name>
                <publisher-loc>London, UK</publisher-loc>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.12688/f1000research.128260.2</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Systematic Review</subject>
                </subj-group>
                <subj-group>
                    <subject>Articles</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Vancomycin Population Pharmacokinetic Models in Non- Critically Ill Adults Patients: a scoping review</article-title>
                <fn-group content-type="pub-status">
                    <fn>
                        <p>[version 2; peer review: 2 approved]</p>
                    </fn>
                </fn-group>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author" corresp="no" equal-contrib="yes">
                    <name>
                        <surname>Nivia</surname>
                        <given-names>Diego</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no" equal-contrib="yes">
                    <name>
                        <surname>Vivas</surname>
                        <given-names>Juan-David</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Brice&#x00f1;o</surname>
                        <given-names>Wilson</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Parra</surname>
                        <given-names>Daniel</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-8289-6140</uri>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Mena</surname>
                        <given-names>Manuel</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Jaimes</surname>
                        <given-names>Diego</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Guevara</surname>
                        <given-names>Juan-Francisco</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0009-0008-9451-6417</uri>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>Bustos</surname>
                        <given-names>Rosa Helena</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="corresp" rid="c1">a</xref>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <aff id="a1">
                    <label>1</label>Department of Pharmacology, Evidence-based Therapeutic Group, Faculty of Medicine, Universidad de La Sabana, Clinica Universidad de La Sabana, Ch&#x00ed;a, Cundinamarca, 140013, Colombia</aff>
            </contrib-group>
            <author-notes>
                <corresp id="c1">
                    <label>a</label>
                    <email xlink:href="mailto:rosa.bustos@unisabana.edu.co">rosa.bustos@unisabana.edu.co</email>
                </corresp>
                <fn fn-type="conflict">
                    <p>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>6</day>
                <month>3</month>
                <year>2025</year>
            </pub-date>
            <pub-date pub-type="collection">
                <year>2022</year>
            </pub-date>
            <volume>11</volume>
            <elocation-id>1513</elocation-id>
            <history>
                <date date-type="accepted">
                    <day>24</day>
                    <month>2</month>
                    <year>2025</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2025 Nivia D et al.</copyright-statement>
                <copyright-year>2025</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <self-uri content-type="pdf" xlink:href="https://f1000research.com/articles/11-1513/pdf"/>
            <abstract>
                <sec>
                    <title>Background</title>
                    <p>Vancomycin is an effective first-line therapy primarily in methicillin-resistant Staphylococcus aureus (MRSA) infection and Clostridium difficile, however, it has been shown that its effectiveness and the reduction of nephrotoxicity depend on maintaining adequate therapeutic levels. Population pharmacokinetic (PopPk) models attempt to parameterize the behavior of plasma concentrations in different target populations and scenarios such as renal replacement therapy, to successful therapeutic outcome and avoid these side effects.</p>
                </sec>
                <sec>
                    <title>Methods</title>
                    <p>A scoping review was conducted following the guidelines of Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR), through a search in PubMed, LILACS, OVID Medline, Scopus, Web of Science, SAGE Journals, Google Scholar and previous known registers of PopPk models in non-critically ill adult patients, published between 1998 and 2024.</p>
                </sec>
                <sec>
                    <title>Results</title>
                    <p>A total of 190 papers were fully screened, of which were included 36 studies conducted in different populations; 12 in general population, 23 in special populations (surgical, with impaired renal function, obese, elderly, with cancer and cystic fibrosis), and 1 in mixed population (general and with cancer). The main parameters in the models were renal clearance and volume of distribution. The principal covariables that affected the models were creatinine clearance and weight. All studies used internal evaluation and 4 of them used an external group.</p>
                </sec>
                <sec>
                    <title>Discussion</title>
                    <p>The technology for the development and implementation of PopPk models requires experts in clinical pharmacology and is limited to university and research centers. The software is mostly expensive and, in most cases, the pharmacokinetic models and the heterogeneity in the parameters and evaluation methods depend on which compartmental model, parameters, covariates and software have been used.</p>
                </sec>
                <sec>
                    <title>Conclusions</title>
                    <p>These models require validation in the clinical context and conducting experiments to adapt them for precision dosing in different subpopulations.</p>
                </sec>
            </abstract>
            <kwd-group kwd-group-type="author">
                <kwd>Population pharmacokinetic</kwd>
                <kwd>vancomycin; non-critically patients.</kwd>
            </kwd-group>
            <funding-group>
                <award-group id="fund-1" xlink:href="https://doi.org/10.13039/501100010628">
                    <funding-source>Universidad de La Sabana</funding-source>
                    <award-id>MED-334-2023</award-id>
                </award-group>
                <funding-statement>This research was funded by Universidad de La Sabana MED-334-2023.</funding-statement>
                <funding-statement>
                    <italic>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</italic>
                </funding-statement>
            </funding-group>
        </article-meta>
        <notes>
            <sec sec-type="version-changes">
                <label>Revised</label>
                <title>Amendments from Version 1</title>
                <p>The revised version of the manuscript reflects the modifications requested by the reviewers. The most significant change in the document is the inclusion of newly identified studies up to November 2024, allowing for a more comprehensive discussion of population pharmacokinetic models of vancomycin in non-critically ill adult patients.</p>
            </sec>
        </notes>
    </front>
    <body>
        <sec id="sec1">
            <title>Introduction</title>
            <p>Vancomycin is a tricycle glycopeptide antibiotic derived from 
                <italic toggle="yes">Streptomyces orientalis</italic>, first used in 1958; by inhibiting the synthesis of the wall, it achieves a high bactericidal power against methicillin-resistant 
                <italic toggle="yes">Staphylococcus aureus</italic> (MRSA), methicillin-susceptible 
                <italic toggle="yes">Staphylococcus aureus</italic> (MSSA), streptococci, enterococci and 
                <italic toggle="yes">Clostridium difficile</italic>.
                <sup>
                    <xref ref-type="bibr" rid="ref1">1</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref2">2</xref>
                </sup> Pharmacokinetic and pharmacodynamic studies of vancomycin suggest that prior trough monitoring is associated with increased nephrotoxicity, with rates between 5% and 43%, related to high doses or high levels of exposure, mainly in special populations such as elderly and critically ill patients.
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref4">4</xref>
                </sup> Therefore, the current dosing and monitoring recommendations of the revised consensus guideline and review by ASHP/PIDS/SIDP/IDSA establish an AUC/MIC ratio of 400&#x2013;600 h
                <sup>&#x2212;1</sup> (assuming a MIC of 1 mg/L) to achieve clinical efficacy and ensure safety for patients treated for serious MRSA infections.
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup>
            </p>
            <p>Although therapeutic drug monitoring (TDM) for vancomycin remains controversial, it has been shown to significantly increase the rate of clinical efficacy and decrease the rate of nephrotoxicity.
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup> TDM of Vancomycin is essential for the development of PopPK models by the use of Bayesian software for AUC estimation and model-informed precision dosing (MIPD), which has been improved outcomes in patients with culture-proven gram-positive infections just with a single concentration monitoring.
                <sup>
                    <xref ref-type="bibr" rid="ref6">6</xref>
                </sup> The PopPK modeling plays a crucial role in optimizing drug dosing regimens, particularly for drugs with a narrow therapeutic index (NTI). NTI drugs, where small changes in drug concentration can result in significant therapeutic consequences, require precise dosing to maximize efficacy and minimize toxicity.
                <sup>
                    <xref ref-type="bibr" rid="ref7">7</xref>
                </sup> PoPK models enable the integration of various physiological, biochemical, and drug-specific factors to predict drug behavior in different patient populations. By simulating a range of dosing scenarios, these models allow for the identification of optimal dosing strategies that balance therapeutic benefit with safety, ensuring that NTI drugs achieve their intended clinical outcomes while avoiding adverse effects. This modeling approach is essential for personalizing therapy, reducing the risk of underdosing or overdosing, and improving patient outcomes.
                <sup>
                    <xref ref-type="bibr" rid="ref8">8</xref>
                </sup>
            </p>
            <p>PopPK is an emerging discipline developed from the combination of classical pharmacokinetic compartment model and statistical principles, which helps to achieve the preliminary prediction of parameters.
                <sup>
                    <xref ref-type="bibr" rid="ref9">9</xref>
                </sup> Despite having been described more than 30 years ago, PopPK models are not widely used due to mathematical complexity, the variety of the study population and limited access to software.
                <sup>
                    <xref ref-type="bibr" rid="ref10">10</xref>
                </sup> This review aims to summarize the main models, software, parameters and covariates in non-critical adult patients that can be used in future applications for MIPD.</p>
        </sec>
        <sec id="sec2" sec-type="methods">
            <title>Methods</title>
            <p>We developed and performed a scoping review of existing reports about PopPK models of vancomycin in adult population out of intensive care. The research protocol was reviewed and approved by the research subcommittee of School of Medicine of Universidad de La Sabana. The review follows the guidelines of Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) and the Johanna Briggs Institute.
                <sup>
                    <xref ref-type="bibr" rid="ref11">11</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref12">12</xref>
                </sup> Reporting checklist extended data E1.</p>
            <p>The primary review question was formulated using the population, concept, context framework, as &#x201c;What are the published vancomycin population pharmacokinetic models with non-critically ill hospitalized adult patients?&#x201d;. Search criteria were established to include studies with: (1) original vancomycin PopPK models, (2) adult patients, and (3) non-critical ill patients; articles were excluded if they: (1) are the wrong publication type, (2) patients are hospitalized in the intensive care or burn unit, (3) do not define equations or parameters, and (4) have a broad range of patients, including critically ill patients. The search was conducted on November 2, 2024, in PubMed, LILACS, OVID Medline, Scopus, Web of Science, SAGE Journals, and Google Scholar, including reports published after January 1998 and some previously known reports in other similar publications. Search terms submitted to each database are presented in 
                <xref ref-type="table" rid="T1">
Table 1</xref>. Only articles published in English, Spanish, or Portuguese were included in the search. The founded references were uploaded into Rayyan (
                <ext-link ext-link-type="uri" xlink:href="http://rayyan.qcri.org">http://rayyan.qcri.org</ext-link>; Headquarter: Cambridge, Massachusetts, U.S.A.), which is a free web and mobile app, that helps expedite the initial screening of abstracts and titles using a process of semi-automation while incorporating a high level of usability.
                <sup>
                    <xref ref-type="bibr" rid="ref13">13</xref>
                </sup> First the detected duplicates in data summary was eliminated by preliminary revision, then the reports were screened and selected for the full text screening to check over the inclusion and exclusion criteria.</p>
            <table-wrap id="T1" orientation="portrait" position="float">
                <label>
Table 1. </label>
                <caption>
                    <title>Search constructs.</title>
                </caption>
                <table content-type="article-table" frame="hsides">
                    <thead>
                        <tr>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Database</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">Search terms</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">PubMed</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">(("vancomycin"[All Fields]) AND ("population pharmacokinetic"[All Fields])) NOT ("critically ill"[All Fields])</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">OVID Medline</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">((population pharmacokinetic* and vancomycin and adult*) not critically).m_titl.</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">LILACS</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">((population pharmacokinetic) AND (vancomycin) AND (adult)) AND NOT (children) AND NOT (neonate) AND NOT (pediatric) AND NOT (critically) AND NOT (intensive care) AND ( mj:("Vancomycin"))</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Web of Science</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">(((((TI=(vancomycin)) AND TI=(population pharmacokinetic)) NOT TI=(critically ill)) NOT TI=(neonates)) NOT TI=(pediatric)) NOT TI=(infants)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">SAGE Journals</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">[Title population pharmacokinetic] AND [Title vancomycin]</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Scopus</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">TITLE (population AND Pharmacokinetic) AND TITLE (vancomycin) AND ALL (adult) AND NOT ALL (critically AND ill) AND NOT ALL (pediatric) AND NOT ALL (children) AND NOT ALL (neonates) AND NOT ALL (infants)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Google Scholar</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">allintitle: population pharmacokinetic vancomycin adult-critically</td>
                        </tr>
                    </tbody>
                </table>
            </table-wrap>
        </sec>
        <sec id="sec3" sec-type="results">
            <title>Results</title>
            <p>We identified 180 records in databases and 10 registers previous included in others publications.
                <sup>
                    <xref ref-type="bibr" rid="ref14">14</xref>
                </sup> After removing duplicates, 155 records remained for screening; 100 were eliminated due to exclusion criteria and 55 reports were assessed for eligibility for full text review; finally, 36 studies were included for this review (
                <xref ref-type="fig" rid="f1">
Figure 1</xref>).</p>
            <fig fig-type="figure" id="f1" orientation="portrait" position="float">
                <label>
Figure 1. </label>
                <caption>
                    <title>Flowchart of studies selected.</title>
                </caption>
                <graphic id="gr1" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/178348/491a7d06-0473-4f53-bd34-44d53fba1438_figure1.gif"/>
            </fig>
            <p>In order to organize the information, they were divided into 8 groups of patients, general (12),
                <sup>
                    <xref ref-type="bibr" rid="ref15">15</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref26">26</xref>
                </sup> surgical (5),
                <sup>
                    <xref ref-type="bibr" rid="ref27">27</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref31">31</xref>
                </sup> with impairment kidney function (7),
                <sup>
                    <xref ref-type="bibr" rid="ref32">32</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref38">38</xref>
                </sup> obese (3),
                <sup>
                    <xref ref-type="bibr" rid="ref39">39</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref41">41</xref>
                </sup> geriatrics (4),
                <sup>
                    <xref ref-type="bibr" rid="ref42">42</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref45">45</xref>
                </sup> with cancer (4),
                <sup>
                    <xref ref-type="bibr" rid="ref15">15</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref46">46</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref48">48</xref>
                </sup> patients with cystic fibrosis (1)
                <sup>
                    <xref ref-type="bibr" rid="ref49">49</xref>
                </sup> and trauma patients (1).
                <sup>
                    <xref ref-type="bibr" rid="ref50">50</xref>
                </sup> Studies published from 1998 to 2024 were found, the mean study by year was 2.3 with an standard deviation (SD) of 1.6 and the years with the highest number of publications were, 2018 (6), 2020 (5), 2019 (4) and 2024 (4). Predominantly, publications of Asian, Middle Eastern, North American and European origin were found; the countries with the highest number of publications were China (9), Japan (6), South Korea (5) and the United States of America (USA) (5). Regarding the design of the study, 27 (75%) were retrospective and 9 (25%) were prospective; the mean of sample size was 217 and SD of sample size was 434,4 (biased by the study of Pai and DeBacker
                <sup>
                    <xref ref-type="bibr" rid="ref36">36</xref>
                </sup> with 2640 patients). 22 (61.1%) of the models were one-compartment and 14 (38.9%) were two-compartment.</p>
            <p>The most commonly used software was NONMEM in 28 studies (77.8%), followed by Monolix 5 (13.9%), Phoenix 2 (5.6%) and R environment with Pmetrics package 1 (2.8%), therefore, 32 (88.9%) of the studies performed a primary analysis and development of the model with Nonlinear mixed-effects modeling (NLME), followed by 3 (8.3%) that used stochastic approximation expectation maximization (SAEM) and 2 (2.8%) performed with nonparametric adaptive grid (NPAG); the most used secondary analyses were first-order conditional estimation (FOCE), first-order conditional estimation with interaction (FOCEI) and first-order conditional estimation with extended least square method (FOCE-ELS) with 19 (52.8%) studies, in addition to objective function value (OFV) with 17 (47.2%) studies and generalized additive model (GAM) with 1 study (7.7%). Almost all models reported internal evaluations, 35 (97.2%) studies, 25 (86.2%) of which reported bootstrap simulations and the methods generally used were goodness-of-fit plots model (GOF), visual predictive checks (VPC), prediction- and variability-corrected VPC (pvcVPC) and numerical predictive check (NPC); only 4 studies reported external evaluations.
                <sup>
                    <xref ref-type="bibr" rid="ref19">19</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref21">21</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref47">47</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref50">50</xref>
                </sup> A summary of demographics and PopPK modeling methods for all the included studies is presented in 
                <xref ref-type="table" rid="T2">
Table 2</xref>.</p>
            <table-wrap id="T2" orientation="portrait" position="float">
                <label>
Table 2. </label>
                <caption>
                    <title>Summary of population group characteristics and modeling methods by year.</title>
                </caption>
                <table content-type="article-table" frame="hsides">
                    <thead>
                        <tr>
                            <th align="left" colspan="1" rowspan="1" valign="top"/>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Year</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Study</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Country</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Study design</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Population</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Sample size, (male/female)</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Age (years), mean (SD) (range)</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
TBW (kg), mean (SD) (range)</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
eGFR (mL/min), mean CL
                                <sub>

                                    <bold>CR</bold>
                                </sub> (SD)(range)</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Compartments</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Software</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Analysis</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Evaluation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td align="left" colspan="1" rowspan="12" valign="middle">
                                <bold>
GENERAL</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1998</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Yasuhara et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref26">26</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Japan</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients infected with MRSA</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">190 (131/59)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">64.3 (13.8)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">52.3 (9.6)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">77.1 (50.9)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Two compartments</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version IV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCE</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: GOF</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2009</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Yamamoto et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref25">25</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Japan</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adult patients with a suspected or documented infection caused by gram positive bacteria and healthy subjects</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">100 (64/36) 6 (6/0)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">65.4 (25.8-99.7) 21.7 (20-25)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">52.6 (28.7-97) 60.3 (55.2-64.2)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">89.3 (10.4)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Two compartments</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 5.1</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCE</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2010</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Tanaka et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref23">23</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Japan</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Prospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients infected with MRSA</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">164 (104/60)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">74 (17-95)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">53 (10)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">65 (14-261)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 5</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2012</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Purwonugroho et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref22">22</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Thailand</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Prospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adult patients</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">212 (112/100)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">66.62 (18.38)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">57.64 (11.62)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">35.07 (29.83)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Two compartments</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2013</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Chung et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref17">17</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">South Korea</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Prospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adult patients with normal serum creatinine</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">678 (400/278)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">56 (18-96)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">62.3 (27-140)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.1</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=2000), GOF, NPC</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2013</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Deng et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref18">18</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">China</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adult patients</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">72 (19/53)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">54.07 (18.36)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">61.12 (10.70)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">82.09 (36.19)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=2000), VPC</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2014</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Lim et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref20">20</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">South Korea</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Prospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients infected with MRSA</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">20 (15/5)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">59.3 (12.9)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">63.1 (15.7)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">96.6 (31.1)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Two compartments</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae;</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCE</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2018</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Ji et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref19">19</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">China</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients who received continuous infusion of vancomycin and were not on renal replacement therapy</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">160 (106/54)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">78 (42-95)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">65 (38-90)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">70.667 (42.74)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.3</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCEI OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=1000), NPDE; External (n= 58)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2018</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Usman et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref24">24</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Germany</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adult patients</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">144 (93/51)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">62 (16-88)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">79.5 (40-177)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">89.8 (11.3-313.6)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCEI</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=1000)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2019</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Liu et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref21">21</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">China</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Prospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adult patients</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">200 (128/72)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">47.4 (15.42)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">61.3 (12.06)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">123.75 (59.96)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.3</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=1000), GOF, VPC; External (n=74)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2019</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Bae et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref16">16</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">South Korea</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adult patients</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">220 (139/81)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">63 (21-98)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">61.6 (30-126.7)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">77.0 (4.57-279)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Two compartments</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.4</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCE</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=1000), pvcVPC</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2020</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Alqahtani et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref15">15</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Saudi Arabia</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adult patients older than 18 years old with cancer and non-cancer
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">74 (44/30)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">55.1 (15.9)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">75.5 (19.7)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">102 (58.8)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Monolix&#x00ae; version 4.4</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">SAEM</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: GOF, pvcVPC</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="5" valign="middle">
                                <bold>SURGICAL</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2016</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Kim et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref29">29</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">South Korea</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Neurosurgical and non-neurosurgical patients</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">30 (14/16) 37 (20/17)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">50.6 (15.0) 61.6 (15.7)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">63.2 (11.6) 61.0 (12.7)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">113.6 (48.3) 79.0 (44)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae;</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCE OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=2000), VPC</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2018</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Alqahtani et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref27">27</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Saudi Arabia</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Prospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients who underwent cardiac surgical</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">28 (17/11)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">51.7 (15.9)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">79.6 (17)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">83.5 (29.3)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Two compartments</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Monolix&#x00ae; version 4.4</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">SAEM</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: GOF, VPC</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2020</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Jing et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref28">28</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">China</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients from the neurosurgery department, aged &#x2265;18 years, receiving vancomycin therapy for &#x2265;72 hours</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">222 (96/126)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">46.95 (12.71)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">60.22 (11.77)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">115.8 (44.64)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.4.3</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCEI OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=2000), GOF, NPDE</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2021</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Munir et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref30">30</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Pakistan</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Prospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients admitted to the surgical unit</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">58 (39/19)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">54 (25-86)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">75 (53-129)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">101.15 (15.9-177.2)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.4.4</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCEI OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=1000), GOF, VPC</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2022</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Wei et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref31">31</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">China</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Postoperative neurosurgical patients</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">560 (370/190)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">52.41 (15.11)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">69.74 (13.05)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">112.74 (30.91)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Phoenix NLME&#x00ae; version 8.3</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCE-ELS
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=5000), GOF, VPC</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="7" valign="middle">
                                <bold>IMPAIRMENT KIDNEY FUNCTION</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1998</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Schaedeli et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref37">37</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Switzerland</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients undergoing long term hemodialysis who received vancomycin for infection therapy or prophylaxis</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">26 (16/10)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">62 (15.2)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">64.7 (13.6)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">4.5 (4.3)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Two compartments</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae;</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCE</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2018</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Zaric et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref38">38</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Serbia</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients with normal renal function and with mild to moderate chronic renal failure</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">32 (21/11) 78 (46/32)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">59.15 (14.46) 67.00 (10.74)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">81.37 (10.11) 78.52 (16.64)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">54.38 (17.70)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Two compartments</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.3</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCE</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=200), GOF</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2019</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Kim DJ et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref33">33</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">South Korea</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients with vancomycin treatment for various infections, and at least two serum concentration measurements</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">99 (59/40)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">64.8 (12.6)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">59.7 (10.98)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">54.49 (36.25)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Two compartments</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.4</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=1000), GOF</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2020</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Ma et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref34">34</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">China</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients who received vancomycin as prophylactic medication following kidney transplant operation</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">56 (35/21)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">43.72 (9.92)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">58.27 (8.47)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">41.95 (25.46)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.4</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCE OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: GOF</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2020</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Pai and DeBacker
                                <sup>
                                    <xref ref-type="bibr" rid="ref36">36</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">USA</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients with stable and unstable kidney disease</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2640 (1689/950)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">59 (16)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">93.9 (28.1)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">63 (39)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Monolix&#x00ae; 2019R2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">SAEM</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=1000), NPDE</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2023</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Oda et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref35">35</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Japan</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective Prospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients (age &#x2265; 18 years) who had received intermittent hemodialysis therapy for end-stage kidney disease</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">28 (8/20)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">61 (14.5)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">57.8 (13.2)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">9.6 (4.7)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Two compartments</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.3; R version 4.1.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap, GOF, pvcVPC</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2024</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Ahmed et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref32">32</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Sudan</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adult patients with renal impairment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">99 (66/33)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">65 (50-75)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">12.7 (5.52-25.78)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Monolix&#x00ae; 2020R1</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME SAEM</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=1000), NPDE, GOF, VPC</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="3" valign="middle">
                                <bold>OBESE</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2015</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adane et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref39">39</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">USA</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Prospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Extremely obese adult patients (BMI &#x2265; 40 kg/m2) with suspected or confirmed Staphylococcus aureus infection</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">31 (19/12)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">43 (38.5-53)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">147.6 (142.8-178.3)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">124.8 (106.0-133.9)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Two compartments</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.3</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCE OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2018</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Crass et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref40">40</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">USA</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Obese (BMI &#x2265; 30 kg/m2) adult patients aged 18&#x2013;90 years who underwent peak and trough vancomycin</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">346 (183/163)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">57 (14)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">132.5 (32.6)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">171 (75)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">R environment Pmetrics
                                <sup>TM</sup> package</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NPAG</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2024</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Pol&#x00e1;skov&#x00e1; et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref41">41</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Czech Republic</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Obese adult patients (age &#x2265; 18years; BMI &#x2265; 30kg/m
                                <sup>2</sup>) treated with intravenous vancomycin during intermittent hemodialysis</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">27 (14/13)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">69 (58-72)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">102 (91.5-118)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Monolix&#x00ae; 2021R2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME SAEM OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=1000), NPDE, GOF</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="4" valign="middle">
                                <bold>GERIATRICS</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2010</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Sanchez et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref43">43</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">USA</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adult and geriatric patients</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">141 (NR)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">55 (14.58)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">73.2 (17.48)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Two compartments</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version VI</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=200)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2019</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Zhou et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref45">45</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">China</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Elderly patients (age &#x2265; 65 years) with HAP or CAP</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">70 (49/21)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">78.3 (6.96)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">60.7 (10.2)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">56.3 (22.1)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.3</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCEI OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=1000), NPDE, GOF</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2020</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Zhang et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref44">44</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">China</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Prospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Elderly patients (age &#x2265; 65 years) infected</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">150 (104/46)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">73.6 (6.83)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">61.7 (1 1.1)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">84.1 (25.6)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.4</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCEI OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=2000), NPDE</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2024</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Ling et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref42">42</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">China</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Inpatients with a diagnosis of MRSA or suspected of having a positive drug resistant bacteria infection</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">313 (201/112)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">72 (65-95)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">65 (38-110)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">70.98 (16.75-165.39)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.3 R version 2.15.1</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=2000), NPDE, GOF</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="4" valign="middle">
                                <bold>CANCER</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2005</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Buelga et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref46">46</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Spain</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adult (15-year-old) in patients with an underlying hematological malignancy admitted for suspected or documented infection caused by gram-positive bacteria</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">215 (119/96)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">51.5 (15.9)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">64.7 (11.3)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">89.4 (39.2)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 5.1.1</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME OFV GAM</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2018</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Okada et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref47">47</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Japan</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients undergoing allo-HSCT who received preventive treatment with vancomycin</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">75 (49/26)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">49 (17-69)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">59.4 (39.4-104.5)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">113 (47-253)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Two compartments</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Phoenix NLME&#x00ae; version 7</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCE-ELS OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=1000), GOF, VPC; external: (20 patients)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2020</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Alqahtani et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref15">15</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Saudi Arabia</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adult patients older than 18 years old with cancer and non-cancer.</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">73 (58/42)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">53.8 (15.7)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">72.7 (16.2)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">102 (58.8)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Monolix&#x00ae; version 4.4</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">SAEM OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: GOF, pvcVPC</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2023</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Tsuda et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref48">48</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Japan</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Patients with solid or hematological malignancy</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">325 (182/143)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">67.8 (14.8)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">54 (12)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">80 (46.7)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.4.3</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCEI OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=1000), GOF, pvcVPC</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">
                                <bold>CYSTIC FIBROSIS</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2024</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Yellepeddi et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref49">49</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">USA</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adults with cystic fibrosis</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">19 (5/14)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">31.2 (12.5)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">63.6 (17.1)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">106.6 (37.9)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">One compartment</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.5</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME FOCEI OFV</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=1000), GOF, VPC</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">
                                <bold>TRAUMA</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2015</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Medell&#x00ed;n-Garibay et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref50">50</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Spain</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Retrospective</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adult patients from the Traumatology service with proven or suspected infection</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">118 (53/65)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">74.3 (14)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">72.0 (15)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">90.5 (51.67)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Two compartments</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NONMEM&#x00ae; version 7.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NLME</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Internal: Bootstrap (n=200); External, (n=40)</td>
                        </tr>
                    </tbody>
                </table>
                <table-wrap-foot>
                    <p>

                        <bold>CL</bold>
                        <sub>

                            <bold>CR</bold>
                        </sub> = Creatinine clearance calculated by Cockcroft-Gault formula; 
                        <bold>eGFR</bold> = estimated glomerular filtration rate; 
                        <bold>FOCE</bold> = first-order conditional estimation; 
                        <bold>FOCEI</bold> = First-order conditional estimation with interaction; 
                        <bold>FOCE-ELS
</bold> = first-order conditional estimation with extended least square method; 
                        <bold>GAM</bold> = generalized additive model; 
                        <bold>GOF</bold> = goodness-of-fit plots model; 
                        <bold>MRSA</bold> = methicillin resistant Staphylococcus aureus; 
                        <bold>NLME</bold> = Nonlinear mixed-effects modeling; 
                        <bold>NPAG</bold> = nonparametric adaptive grid; 
                        <bold>NPC</bold> = numerical predictive check; 
                        <bold>NPDE</bold> = normalized prediction distribution errors; 
                        <bold>NR</bold> = no reported; 
                        <bold>OFV</bold> = objective function value; 
                        <bold>pvcVPC</bold> = prediction- and variability-corrected VPC; 
                        <bold>SAEM</bold> = stochastic approximation expectation maximization; 
                        <bold>SD</bold> = standard deviation; 
                        <bold>USA</bold> = United States of America; 
                        <bold>VPC</bold> = visual predictive checks.</p>
                </table-wrap-foot>
            </table-wrap>
            <p>The combined mean and combined SD of age did not differ much from the combined means and SD by groups, being for all 59.74 years and 17.24 years respectively; as for the total body weight (TBW) the obese group presented a combined mean of 131.62 kg with a combined SD of 31.59 kg, while the total of the groups had a combined mean of 76.98 kg and a combined SD of 21.25 kg; for the estimated glomerular filtration rate (eGFR) greater heterogeneity was found, since in the group with impaired kidney function the combined means and SD were 59.55 ml/min and 44.54 ml/min respectively, while in the total the combined mean of the eGFR was 80.42 ml/min and the combined SD was 54.07 ml/min (see Extended data E2 Additional results tables).</p>
            <p>Most of the equations presented by the PopPK models are in the form in which the expressions for clearance (CL), distribution volumes (V
                <sub>i</sub>), intercompartmental clearance (Q) and elimination transfer rate constants (k
                <sub>12</sub>, k
                <sub>21</sub>), are equal to the estimates of the population mean of each study (CLpop, V
                <sub>i</sub>pop, Qpop, k
                <sub>12</sub>pop, k
                <sub>21</sub>pop) or typical values (TVCL, TVV
                <sub>i</sub>, TVQ, TVk
                <sub>12</sub>, TVk
                <sub>21</sub>), which as in the case of CL are generally affected proportionally or additively by covariates, in greater proportion by the renal clearance (CL
                <sub>CR</sub>) or the estimated glomerular filtration rate (eGFR) by Cockroft-Gault, although the studies by Chung et al.
                <sup>
                    <xref ref-type="bibr" rid="ref17">17</xref>
                </sup> and Ling et al.
                <sup>
                    <xref ref-type="bibr" rid="ref42">42</xref>
                </sup> uses cystatin C to affect the TVCL or the study by Medell&#x00ed;n-Garibay
                <sup>
                    <xref ref-type="bibr" rid="ref50">50</xref>
                </sup> and Wei et al.
                <sup>
                    <xref ref-type="bibr" rid="ref31">31</xref>
                </sup> they associate furosemide or mannitol respectively as factors that alter eGFR, for these models serum creatinine or CLCR are also included as covariates. Furosemide was not directly used to estimate the glomerular filtration rate (GFR). Instead, it was administered as part of a furosemide stress test, which has been proposed as a functional marker of renal reserve. This test assesses renal response to a standardized dose of furosemide and has been used to predict acute kidney injury (AKI) progression in critically ill patients. However, in the context of the referenced study, cystatin C was the primary biomarker used for GFR estimation.</p>
            <p>To a lesser extent, total body weight (TBW) or age are reported as covariates for TVCL, other models include clinical conditions such as the use of hemodialysis (HD),
                <sup>
                    <xref ref-type="bibr" rid="ref16">16</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref35">35</xref>
                </sup> continuous renal replacement therapy (CRRT)
                <sup>
                    <xref ref-type="bibr" rid="ref16">16</xref>
                </sup> or intermittent renal replacement therapy (IRRT)
                <sup>
                    <xref ref-type="bibr" rid="ref37">37</xref>
                </sup>; there are models such as that of Kim et al.
                <sup>
                    <xref ref-type="bibr" rid="ref29">29</xref>
                </sup> that includes as covariates being a neurosurgical patient, presenting underlying liver cirrhosis or co-administration of nephrotoxic drugs; the most recent model such as that of Tsuda et al.
                <sup>
                    <xref ref-type="bibr" rid="ref48">48</xref>
                </sup> even includes quick SOFA (qSOFA) as a covariate. Other covariates only presented once per model, such as sex,
                <sup>
                    <xref ref-type="bibr" rid="ref40">40</xref>
                </sup> daily dose of vancomycin and AST,
                <sup>
                    <xref ref-type="bibr" rid="ref38">38</xref>
                </sup> albumin
                <sup>
                    <xref ref-type="bibr" rid="ref27">27</xref>
                </sup> and post-craniotomy meningitis.
                <sup>
                    <xref ref-type="bibr" rid="ref44">44</xref>
                </sup>
            </p>
            <p>Regarding distribution volumes, they are most commonly reported as equal to TVVi if expressed in liters (L) or as the relative TVVi by TBW if expressed in L/kg. In some equations, age can also influence these values. The most reported equation patterns for CL, V
                <sub>i</sub>, Q, k12, and k21 are:
                <disp-formula id="e1">

                    <mml:math display="block">
                        <mml:mi mathvariant="normal">CL</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:mtext>TVCL</mml:mtext>
                        <mml:mo>&#x00d7;</mml:mo>
                        <mml:msup>
                            <mml:mfenced close=")" open="(">
                                <mml:mrow>
                                    <mml:msub>
                                        <mml:mi mathvariant="normal">CL</mml:mi>
                                        <mml:mi mathvariant="normal">CR</mml:mi>
                                    </mml:msub>
                                    <mml:mo>/</mml:mo>
                                    <mml:msub>
                                        <mml:mover accent="true">
                                            <mml:mi mathvariant="normal">CL</mml:mi>
                                            <mml:mo stretchy="true">&#x00af;</mml:mo>
                                        </mml:mover>
                                        <mml:mi mathvariant="normal">CR</mml:mi>
                                    </mml:msub>
                                </mml:mrow>
                            </mml:mfenced>
                            <mml:msub>
                                <mml:mi mathvariant="normal">&#x03b8;</mml:mi>
                                <mml:msub>
                                    <mml:mi mathvariant="normal">CL</mml:mi>
                                    <mml:mi mathvariant="normal">CR</mml:mi>
                                </mml:msub>
                            </mml:msub>
                        </mml:msup>
                    </mml:math>
</disp-formula>

                <disp-formula id="e2">

                    <mml:math display="block">
                        <mml:mi mathvariant="normal">CL</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:msub>
                            <mml:mi mathvariant="normal">&#x03b8;</mml:mi>
                            <mml:msub>
                                <mml:mi mathvariant="normal">CL</mml:mi>
                                <mml:mi mathvariant="normal">CR</mml:mi>
                            </mml:msub>
                        </mml:msub>
                        <mml:mo>&#x00d7;</mml:mo>
                        <mml:msub>
                            <mml:mi mathvariant="normal">CL</mml:mi>
                            <mml:mi mathvariant="normal">CR</mml:mi>
                        </mml:msub>
                    </mml:math>
</disp-formula>

                <disp-formula id="e3">

                    <mml:math display="block">
                        <mml:mi mathvariant="normal">CL</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:mtext>TVCL</mml:mtext>
                    </mml:math>
</disp-formula>

                <disp-formula id="e4">

                    <mml:math display="block">
                        <mml:mi mathvariant="normal">CL</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:mtext>TVCL</mml:mtext>
                        <mml:mo>+</mml:mo>
                        <mml:mfenced close=")" open="(">
                            <mml:mrow>
                                <mml:msub>
                                    <mml:mi mathvariant="normal">&#x03b8;</mml:mi>
                                    <mml:msub>
                                        <mml:mi mathvariant="normal">CL</mml:mi>
                                        <mml:mi mathvariant="normal">CR</mml:mi>
                                    </mml:msub>
                                </mml:msub>
                                <mml:mo>&#x00d7;</mml:mo>
                                <mml:msub>
                                    <mml:mi mathvariant="normal">CL</mml:mi>
                                    <mml:mi mathvariant="normal">CR</mml:mi>
                                </mml:msub>
                            </mml:mrow>
                        </mml:mfenced>
                    </mml:math>
</disp-formula>

                <disp-formula id="e5">

                    <mml:math display="block">
                        <mml:mi mathvariant="normal">CL</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:mtext>TVCL</mml:mtext>
                        <mml:mo>&#x00d7;</mml:mo>
                        <mml:msup>
                            <mml:mfenced close=")" open="(">
                                <mml:mrow>
                                    <mml:mi mathvariant="normal">TBW</mml:mi>
                                    <mml:mo>/</mml:mo>
                                    <mml:mover accent="true">
                                        <mml:mi mathvariant="normal">TBW</mml:mi>
                                        <mml:mo stretchy="true">&#x00af;</mml:mo>
                                    </mml:mover>
                                </mml:mrow>
                            </mml:mfenced>
                            <mml:msub>
                                <mml:mi mathvariant="normal">&#x03b8;</mml:mi>
                                <mml:mi mathvariant="normal">TBW</mml:mi>
                            </mml:msub>
                        </mml:msup>
                    </mml:math>
</disp-formula>

                <disp-formula id="e6">

                    <mml:math display="block">
                        <mml:mi mathvariant="normal">CL</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:mtext>TVCL</mml:mtext>
                        <mml:mo>&#x00d7;</mml:mo>
                        <mml:mfenced close=")" open="(">
                            <mml:mrow>
                                <mml:msub>
                                    <mml:mi mathvariant="normal">CL</mml:mi>
                                    <mml:mi mathvariant="normal">CR</mml:mi>
                                </mml:msub>
                                <mml:mo>/</mml:mo>
                                <mml:msub>
                                    <mml:mover accent="true">
                                        <mml:mi mathvariant="normal">CL</mml:mi>
                                        <mml:mo stretchy="true">&#x00af;</mml:mo>
                                    </mml:mover>
                                    <mml:mi mathvariant="normal">CR</mml:mi>
                                </mml:msub>
                            </mml:mrow>
                        </mml:mfenced>
                    </mml:math>
</disp-formula>

                <disp-formula id="e7">

                    <mml:math display="block">
                        <mml:mi mathvariant="normal">CL</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:mtext>TVCL</mml:mtext>
                        <mml:mo>&#x00d7;</mml:mo>
                        <mml:msup>
                            <mml:mfenced close=")" open="(">
                                <mml:mrow>
                                    <mml:msub>
                                        <mml:mi mathvariant="normal">CL</mml:mi>
                                        <mml:mi mathvariant="normal">CR</mml:mi>
                                    </mml:msub>
                                    <mml:mo>/</mml:mo>
                                    <mml:msub>
                                        <mml:mover accent="true">
                                            <mml:mi mathvariant="normal">CL</mml:mi>
                                            <mml:mo stretchy="true">&#x00af;</mml:mo>
                                        </mml:mover>
                                        <mml:mi mathvariant="normal">CR</mml:mi>
                                    </mml:msub>
                                </mml:mrow>
                            </mml:mfenced>
                            <mml:msub>
                                <mml:mi mathvariant="normal">&#x03b8;</mml:mi>
                                <mml:msub>
                                    <mml:mi mathvariant="normal">CL</mml:mi>
                                    <mml:mi mathvariant="normal">CR</mml:mi>
                                </mml:msub>
                            </mml:msub>
                        </mml:msup>
                        <mml:mo>&#x00d7;</mml:mo>
                        <mml:msup>
                            <mml:mfenced close="]" open="[">
                                <mml:mrow>
                                    <mml:mi mathvariant="normal">TBW</mml:mi>
                                    <mml:mo>/</mml:mo>
                                    <mml:mover accent="true">
                                        <mml:mi mathvariant="normal">TBW</mml:mi>
                                        <mml:mo stretchy="true">&#x00af;</mml:mo>
                                    </mml:mover>
                                </mml:mrow>
                            </mml:mfenced>
                            <mml:msub>
                                <mml:mi mathvariant="normal">&#x03b8;</mml:mi>
                                <mml:mi mathvariant="normal">TBW</mml:mi>
                            </mml:msub>
                        </mml:msup>
                    </mml:math>
</disp-formula>

                <disp-formula id="e8">

                    <mml:math display="block">
                        <mml:msub>
                            <mml:mi mathvariant="normal">V</mml:mi>
                            <mml:mi mathvariant="normal">i</mml:mi>
                        </mml:msub>
                        <mml:mo>=</mml:mo>
                        <mml:mi mathvariant="normal">TVV</mml:mi>
                    </mml:math>
</disp-formula>

                <disp-formula id="e9">

                    <mml:math display="block">
                        <mml:msub>
                            <mml:mi mathvariant="normal">V</mml:mi>
                            <mml:mi mathvariant="normal">i</mml:mi>
                        </mml:msub>
                        <mml:mo>=</mml:mo>
                        <mml:mtext>TVV</mml:mtext>
                        <mml:mo>&#x00d7;</mml:mo>
                        <mml:mtext>TBW</mml:mtext>
                    </mml:math>
</disp-formula>

                <disp-formula id="e10">

                    <mml:math display="block">
                        <mml:mi mathvariant="normal">Q</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:mi mathvariant="normal">TVQ</mml:mi>
                    </mml:math>
</disp-formula>

                <disp-formula id="e11">

                    <mml:math display="block">
                        <mml:msub>
                            <mml:mi mathvariant="normal">k</mml:mi>
                            <mml:mn>12</mml:mn>
                        </mml:msub>
                        <mml:mo>=</mml:mo>
                        <mml:msub>
                            <mml:mi mathvariant="normal">TVk</mml:mi>
                            <mml:mn>12</mml:mn>
                        </mml:msub>
                    </mml:math>
</disp-formula>

                <disp-formula id="e12">

                    <mml:math display="block">
                        <mml:msub>
                            <mml:mi mathvariant="normal">k</mml:mi>
                            <mml:mn>21</mml:mn>
                        </mml:msub>
                        <mml:mo>=</mml:mo>
                        <mml:msub>
                            <mml:mi mathvariant="normal">TVk</mml:mi>
                            <mml:mn>21</mml:mn>
                        </mml:msub>
                    </mml:math>
</disp-formula>
            </p>
            <p>The main features and values of the equations, parameters, population mean (VT) and variability are shown in 
                <xref ref-type="table" rid="T3">
Table 3</xref>. Many of the studies do not explicitly show TV for which we calculate with measures of central tendency for the reported covariates and substituting them in the covariate equations in the final model; although most studies with two-compartment models reported parameters in the form of flow rates (CL and Q), two studies reported model parameters in the form of elimination, transfer rate constants (k
                <sub>12</sub>, k
                <sub>21</sub>) were presented, in order to make comparisons among studies, the conversion of parameters in the form of flow rates was implemented with the following equation:
                <disp-formula id="e13">

                    <mml:math display="block">
                        <mml:mi mathvariant="normal">Q</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:msub>
                            <mml:mi mathvariant="normal">k</mml:mi>
                            <mml:mn>12</mml:mn>
                        </mml:msub>
                        <mml:mo>&#x00d7;</mml:mo>
                        <mml:msub>
                            <mml:mi mathvariant="normal">V</mml:mi>
                            <mml:mn>1</mml:mn>
                        </mml:msub>
                    </mml:math>
</disp-formula>
            </p>
            <table-wrap id="T3" orientation="portrait" position="float">
                <label>
Table 3. </label>
                <caption>
                    <title>Main features of the published PopPk models.</title>
                </caption>
                <table content-type="article-table" frame="hsides">
                    <thead>
                        <tr>
                            <th align="left" colspan="1" rowspan="2" valign="top"/>
                            <th align="left" colspan="1" rowspan="2" valign="top">
Study</th>
                            <th align="left" colspan="3" rowspan="1" valign="top"/>
                            <th align="left" colspan="3" rowspan="1" valign="top">Volume of distribution related expressions: V
                                <sub>

                                    <bold>i</bold>
                                </sub> (L)</th>
                            <th align="left" colspan="2" rowspan="1" valign="top">Population mean (TV)</th>
                            <th align="left" colspan="2" rowspan="1" valign="top">BSV (&#x03c9;)</th>
                            <th align="left" colspan="2" rowspan="1" valign="top">RV (
                                <italic toggle="yes">a</italic>),(
                                <italic toggle="yes">b</italic>)</th>
                        </tr>
                        <tr>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Equations</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Parameter</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Value</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Equations</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Parameter</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Value</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
CL (L/h), Q (L/h), k
                                <sub>

                                    <bold>ij</bold>
                                </sub> (h
                                <sup>

                                    <bold>-1</bold>
                                </sup>)</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
V
                                <sub>

                                    <bold>i</bold>
                                </sub> (L)</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
CL</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
V
                                <sub>

                                    <bold>i</bold>
                                </sub>
                            </th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Additive (mg/L)</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Proportional</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td align="left" colspan="1" rowspan="13" valign="middle">
                                <bold>
GENERAL</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Yasuhara et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref26">26</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL
                                <sub>CR</sub> &#x2264; 85 mL/min:
                                <break/>CL = &#x03b8;
                                <sub>1</sub> &#x00d7; CL
                                <sub>CR</sub>
                                <break/>CL
                                <sub>CR</sub> &gt; 85 mL/min:
                                <break/>CL = &#x03b8;
                                <sub>2</sub> k
                                <sub>12</sub> = &#x03b8;
                                <sub>3</sub> k
                                <sub>21</sub> = &#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.0478
                                <break/>3.51
                                <break/>0.525
                                <break/>0.213</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>ss</sub> = &#x03b8;
                                <sub>5</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>5</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">60,7</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">3.51</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">60.7</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">38.5%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>ss</sub> = 25.4%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">23.7%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Yamamoto et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref25">25</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL
                                <sub>CR</sub> &gt; 85 mL/min:
                                <break/>CL = &#x03b8;
                                <sub>1</sub>
                                <break/>CL
                                <sub>CR</sub> &#x2264; 85 mL/min:
                                <break/>CL = &#x03b8;
                                <sub>2</sub> &#x00d7; CL
                                <sub>CR</sub> + &#x03b8;
                                <sub>3</sub> Q = &#x03b8;
                                <sub>8</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                                <break/>&#x03b8;
                                <sub>8</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">3.83
                                <break/>0.0322
                                <break/>0.32 8.81</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = &#x03b8;
                                <sub>4</sub> &#x00d7; (1 + (&#x03b8;
                                <sub>5</sub> &#x00d7; STATUS)) &#x00d7; TBW V
                                <sub>2</sub> = &#x03b8;
                                <sub>6</sub> + (STATUS &#x00d7; &#x03b8;
                                <sub>7</sub>)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>4</sub>
                                <break/>&#x03b8;
                                <sub>5</sub>
                                <break/>&#x03b8;
                                <sub>6</sub>
                                <break/>&#x03b8;
                                <sub>7</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.206
                                <break/>0.272
                                <break/>39.4
                                <break/>21.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = 3.83
                                <break/>Q = 8.81</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 28.82
                                <break/>V
                                <sub>2</sub> = 60.6</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">37.5%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 18.2%
                                <break/>V
                                <sub>2</sub> = 72.8%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">14.3%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Tanaka et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref23">23</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL (ml/min) = &#x03b8;
                                <sub>1</sub> &#x00d7; eGFR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.875</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V (L/kg) = &#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.864</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.68</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">45.79</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">19.8%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">30.7%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">12.7</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Purwonugroho et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref22">22</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; CL
                                <sub>CR</sub> (mL/min) Q = &#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.044
                                <break/>6.950</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = &#x03b8;
                                <sub>2</sub> &#x00d7; Age
                                <break/>V
                                <sub>2</sub> = &#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.542
                                <break/>44.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = 1.56
                                <break/>Q = 6.95</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 36.11
                                <break/>V
                                <sub>2</sub> = 44.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">35.78%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 20.93%
                                <break/>V
                                <sub>2</sub> = 57.27%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">4.51</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">
                                <styled-content style="#212121" style-type="color">Chung</styled-content> et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref17">17</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = 4.9 &#x00d7; (1 + &#x03b8;
                                <sub>1</sub> &#x00d7; [AGE-57]) &#x00d7; (1 + &#x03b8;
                                <sub>2</sub> &#x00d7; [TBW - 60.8]) &#x00d7; (1 + &#x03b8;
                                <sub>3</sub> &#x00d7; [SCr - 0.8]) &#x00d7; (CystatinC/0.91)^&#x03b8;
                                <sub>4</sub> if female, apply 1 + &#x03b8;
                                <sub>5</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                                <break/>&#x03b8;
                                <sub>5</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">-0.0042
                                <break/>0.00997 -0.322
                                <break/>-0.780
                                <break/>-0.150</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = 46.2&#x00d7; (1 + &#x03b8;
                                <sub>6</sub> &#x00d7; [AGE-57]) &#x00d7; (1+ &#x03b8;
                                <sub>7</sub> &#x00d7; [TBW-60.8]) if female, apply 1 + &#x03b8;
                                <sub>8</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>6</sub>
                                <break/>&#x03b8;
                                <sub>7</sub>
                                <break/>&#x03b8;
                                <sub>8</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.00580
                                <break/>0.00661
                                <break/>-0.119</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">4.90</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">46.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">26.2%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">37.3%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1.40</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">6.39%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Deng et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref18">18</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CLCR &lt; 80 mL/min:
                                <break/>CL = &#x03b8;
                                <sub>1</sub> &#x00d7; CL
                                <sub>CR</sub>
                                <break/>CLCR &#x2265; 80 mL/min:
                                <break/>CL = &#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.0654
                                <break/>4.9</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">47.76</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">4.90</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">47.76</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">45.35 %</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">39.25 %</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1.21</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">30.71%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Lim et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref20">20</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; CL
                                <sub>CR</sub>/100 Q = &#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">3.96 6.99</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = &#x03b8;
                                <sub>2</sub>
                                <break/>V
                                <sub>2</sub> = &#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">33.1
                                <break/>48.3</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = 3.96
                                <break/>Q = 6.99</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 33.1
                                <break/>V
                                <sub>2</sub> = 48.3</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">40.1%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">35.7%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.231 (SD)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Medell&#x00ed;n-Garibay et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref50">50</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Furosemide = 0:
                                <break/>CL = &#x03b8;
                                <sub>1</sub> &#x00d7; CL
                                <sub>CR</sub> Furosemide = 1:
                                <break/>CL = &#x03b8;
                                <sub>5</sub> &#x00d7; CL
                                <sub>CR</sub> Q = &#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>5</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.49
                                <break/>0.34
                                <break/>0.81</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">If age &gt; 65 years:
                                <break/>V
                                <sub>1</sub> (L/kg) = &#x03b8;
                                <sub>2</sub> &#x00d7; TBW V
                                <sub>2</sub> (L/kg) = &#x03b8;
                                <sub>4</sub> &#x00d7; TBW If age &#x2264; 65 years: V
                                <sub>1</sub> (L/kg) = &#x03b8;
                                <sub>6</sub> &#x00d7; TBW</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                                <break/>&#x03b8;
                                <sub>6</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1.07
                                <break/>5.99
                                <break/>0.74</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = 2.6 (1.85)
                                <break/>Q = 0.81</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 77.4 (53.28)
                                <break/>V
                                <sub>2</sub> = 424.8</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">36.2%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 37.1%
                                <break/>V
                                <sub>2</sub> = NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">19.3%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Ji et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref19">19</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; (1 + &#x03b8;
                                <sub>2</sub> &#x00d7; [CL
                                <sub>CR</sub> - 80]) &#x00d7; (75/AGE)^&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.829
                                <break/>0.00842
                                <break/>0.8143</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">52.14</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.829</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">52.14</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">32.42%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">28.87%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.64</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">26.79%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Usman et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref24">24</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; (1 + &#x03b8;
                                <sub>2</sub> &#x00d7; [CL
                                <sub>CR</sub> &#x2212; &#x03b8;
                                <sub>3</sub>])</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.32
                                <break/>0.0018
                                <break/>89.8</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">19.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.32</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">19.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">20.40%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">38.50%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Liu et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref21">21</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; (eGFR/105.5)^&#x03b8;
                                <sub>2</sub> &#x00d7; (AGE/48.5)^&#x03b8;
                                <sub>3</sub> &#x00d7; (TBW/60)^&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">5.07
                                <break/>0.524
                                <break/>-0.309
                                <break/>0.491</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>5</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>5</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">46.3</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">5.07</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">46.3</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">20.80%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">18.10%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1.28</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">15.90%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Bae et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref16">16</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; (CL
                                <sub>CR</sub>/72)^&#x03b8;
                                <sub>2</sub>
                                <break/>CL
                                <sub>CRRT</sub> = &#x03b8;
                                <sub>3</sub>
                                <break/>CL
                                <sub>HD</sub> = &#x03b8;
                                <sub>4</sub> Q = &#x03b8;
                                <sub>6</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                                <break/>&#x03b8;
                                <sub>6</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.82
                                <break/>0.836
                                <break/>0.716
                                <break/>0.334
                                <break/>11.7</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = &#x03b8;
                                <sub>4</sub>
                                <break/>V
                                <sub>2</sub> = &#x03b8;
                                <sub>5</sub> &#x00d7; (TBW/60)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>4</sub>
                                <break/>&#x03b8;
                                <sub>5</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">31.8 75.4</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = 2.80
                                <break/>Q = 11.7</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 31.8
                                <break/>V
                                <sub>2</sub> = 75.4</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">99.20%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = NR
                                <break/>V
                                <sub>2</sub> = 49.20%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.253 (SD)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Alqahtani et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref15">15</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; (CL
                                <sub>CR</sub>/96.3)^&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">5.6
                                <break/>0.18</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">42</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">5.6</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">42</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">20.3%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">18.2%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">23%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="5" valign="middle">
                                <bold>SURGICAL</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Kim et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref29">29</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = [early phase &#x03b8;
                                <sub>1</sub> or late phase &#x03b8;
                                <sub>2</sub>] &#x00d7; (CL
                                <sub>CR</sub>/95.8) &#x00d7; &#x03b8;
                                <sub>3</sub>
                                <sup>TO&#x00d7;I</sup> &#x00d7; &#x03b8;
                                <sub>4</sub>
                                <sup>LC</sup> + &#x03b8;
                                <sub>5</sub>
                                <sup>NEUR</sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                                <break/>&#x03b8;
                                <sub>5</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">4.36
                                <break/>3.69
                                <break/>0.811
                                <break/>0.511
                                <break/>2.42</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = [early phase &#x03b8;
                                <sub>6</sub> or late phase &#x03b8;
                                <sub>7</sub>]</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>6</sub>
                                <break/>&#x03b8;
                                <sub>7</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">83.7 (107)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">4.36 (3.69)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">83.7 (107)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.125 variance</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1.92</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">8.59%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Alqahtani et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref27">27</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; (CL
                                <sub>CR</sub>/83.5)^0.514 &#x00d7; (ALBUMIN/35.5)^0.854 Q = &#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">6.13
                                <break/>0.22</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = &#x03b8;
                                <sub>3</sub> &#x00d7; (TBW/79.6)^0.466
                                <break/>V
                                <sub>2</sub> = &#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>3</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">40 3.88</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = 6.13
                                <break/>Q = 0.22</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 40
                                <break/>V
                                <sub>2</sub> = 3.88</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">22.1%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 6.34%
                                <break/>V
                                <sub>2</sub> = 61.2%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.055</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">15.2%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Jing et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref28">28</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = [6.4 &#x00d7; (eGFR/128)^&#x03b8;
                                <sub>1</sub> &#x00d7; (TBW/60) (AGE/47)^&#x03b8;
                                <sub>3</sub>] &#x00d7; e&#x00d7;p^&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.515
                                <break/>0.417
                                <break/>0.267
                                <break/>0.0417</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">60.1</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">6.49</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">60.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">7%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">9%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Munir et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref30">30</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">By CL
                                <sub>CR</sub>:
                                <break/>CL = 1 + &#x03b8;
                                <sub>1</sub> &#x00d7; (CL
                                <sub>CR</sub> &#x2212; 101.15) By TBW:
                                <break/>CL = 1 &#x2212; &#x03b8;
                                <sub>2</sub> &#x00d7; (TBW &#x2212; 75)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.0046
                                <break/>0.011</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">22.6</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.45</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">22.6</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">11.3%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">22.8%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">3.07</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Wei et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref31">31</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = 7.98 &#x00d7; (eGFR/115.2)^&#x03b8;
                                <sub>1</sub> &#x00d7; (TBW/70)^&#x03b8;
                                <sub>2</sub> &#x00d7; e&#x00d7;p^A with mannitol, A = 0.13; otherwise, A = 0</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.8 0.3</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">60.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">7.98</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">60.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">48.19%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.73</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">13.06%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="7" valign="middle">
                                <bold>RENAL</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Schaedeli et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref37">37</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL
                                <sub>CR</sub> &#x2265; 2 mL/min:
                                <break/>CL = &#x03b8;
                                <sub>1</sub>+ &#x03b8;
                                <sub>2</sub> &#x00d7; CL
                                <sub>CR</sub>
                                <break/>CL
                                <sub>CR</sub> &lt; 2 mL/min:
                                <break/>CL = &#x03b8;
                                <sub>1</sub>
                                <break/>CLDv = &#x03b8;
                                <sub>3</sub> &#x00d7; CLD
                                <sub>BUN</sub> k
                                <sub>12</sub> = &#x03b8;
                                <sub>5</sub> k
                                <sub>21</sub> = &#x03b8;
                                <sub>6</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                                <break/>&#x03b8;
                                <sub>5</sub>
                                <break/>&#x03b8;
                                <sub>6</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.25
                                <break/>0.585
                                <break/>0.336
                                <break/>0.872
                                <break/>0.162</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>c</sub> = &#x03b8;
                                <sub>4</sub> &#x00d7; TBW
                                <break/>V
                                <sub>ss</sub> = &#x03b8;
                                <sub>5</sub> &#x00d7; TBW</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>4</sub>
                                <break/>&#x03b8;
                                <sub>5</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.164
                                <break/>1.05</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = 2.25
                                <break/>k
                                <sub>12</sub> = 0.872
                                <break/>k
                                <sub>21</sub> = 0.162</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>ss</sub> = 67.93</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CLCR &lt; 2 mL/min: Cl = 90% CLCR &#x2265; 2 mL/min: Cl = 32%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">22%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">13%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Zaric et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref38">38</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Normal renal function:
                                <break/>CL = &#x03b8;
                                <sub>1</sub> + &#x03b8;
                                <sub>3</sub> &#x00d7; FIB Impaired renal function:
                                <break/>CL = &#x03b8;
                                <sub>2</sub> + &#x03b8;
                                <sub>4</sub> &#x00d7; DD + 0.00194 &#x00d7; AST</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                                <break/>&#x03b8;
                                <sub>5</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.0727
                                <break/>0.284
                                <break/>0.205
                                <break/>0.000596
                                <break/>0.00194</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Normal renal function: V
                                <sub>1</sub> = &#x03b8;
                                <sub>6</sub> Impaired renal function: V
                                <sub>1</sub> = &#x03b8;
                                <sub>7</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>6</sub>
                                <break/>&#x03b8;
                                <sub>7</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">7.47
                                <break/>29.9</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.284</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">29.9</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.059 variance 0.135 variance</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.05 variance 0.045 variance</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Kim DJ et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref33">33</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; [(&#x03b8;
                                <sub>2</sub>/ eGFR
                                <sub>base</sub>) + (eGFR
                                <sub>at time</sub>/eGFR
                                <sub>median</sub>)] Q = &#x03b8;
                                <sub>5</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>5</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.21
                                <break/>0.921
                                <break/>3.06</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = &#x03b8;
                                <sub>3</sub>
                                <break/>V
                                <sub>2</sub> = &#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>3</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">32.6
                                <break/>45.8</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = 2.21
                                <break/>Q = 3.06</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 32.6
                                <break/>V
                                <sub>2</sub> = 45.8</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">5.3%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = NR V
                                <sub>2</sub> = 32%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1.95</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">14.3%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Ma et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref34">34</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; [(TBW/59.95)^&#x03b8;
                                <sub>2</sub>] &#x00d7; [(eGFR/36.67)^&#x03b8;
                                <sub>3</sub>]</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.08
                                <break/>0.698
                                <break/>1.07</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>4</sub> &#x00d7; [(TBW/59.95)^&#x03b8;
                                <sub>5</sub>]</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>4</sub>
                                <break/>&#x03b8;
                                <sub>5</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">63.2
                                <break/>0.934</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.08</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">63.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">21.5%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">24.2%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Pai and DeBacker
                                <sup>
                                    <xref ref-type="bibr" rid="ref36">36</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = e&#x00d7;p(&#x03b8;
                                <sub>1</sub> + &#x03b8;
                                <sub>2</sub> &#x00d7; (eGFR/100)) - &#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1.03
                                <break/>0.737
                                <break/>-1.63</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">66.4</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.334</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">66.4</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">(0.44, 0.85) IQR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">(60.5, 98.2) IQR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.76</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Oda et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref35">35</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; (TBW/70)^0.75 &#x00d7; e&#x00d7;p (&#x03b7;
                                <sub>CL</sub>) + unbound fraction &#x00d7; KoA-predicted CL
                                <sub>HD</sub> if (during HD) 1 else 0 k
                                <sub>12</sub> = &#x03b8;
                                <sub>3</sub> k
                                <sub>21</sub> = &#x03b8;
                                <sub>4</sub> &#x00d7; e&#x00d7;p (&#x03b7;
                                <sub>k21</sub>) &#x03b7;
                                <sub>(CL,K21)</sub> is a random variable number depending on the mean of zero with a variance of &#x03c9;
                                <sup>2</sup>
                                <sub>(CL,k21)</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.316
                                <break/>0.525
                                <break/>0.213</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>SS</sub> = &#x03b8;
                                <sub>2</sub> &#x00d7; TBW &#x00d7; e&#x00d7;p (&#x03b7;
                                <sub>Vss</sub>) &#x03b7;
                                <sub>Vss</sub> is a random variable number depending on the mean of zero with a variance of &#x03c9;
                                <sup>2</sup>
                                <sub>Vss</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1.160</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = 0.316
                                <break/>k
                                <sub>12</sub> = 0.525
                                <break/>k
                                <sub>21</sub> = 0.213</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>SS</sub> = 67.05</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.365 variance</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.302 variance</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.064 variance</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Ahmed et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref32">32</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; TZ
                                <sub>R</sub>^&#x03b8;
                                <sub>2</sub> &#x00d7; e&#x00d7;p (&#x03b7;
                                <sub>CL</sub>) &#x03b7;
                                <sub>CL</sub> is a random variable number depending on the mean of zero with a variance of &#x03c9;
                                <sup>2</sup>
                                <sub>CL</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.02
                                <break/>40.49</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>2</sub> &#x00d7; e&#x00d7;p (&#x03b7;
                                <sub>V</sub>) &#x03b7;
                                <sub>V</sub> is a random variable number depending on the mean of zero with a variance of &#x03c9;
                                <sup>2</sup>
                                <sub>V</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">65</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.02</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">65</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.46 (SD)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.39 (SD)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.28 (SD)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="3" valign="middle">
                                <bold>OBESE</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Adane et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref39">39</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>2</sub> &#x00d7; (CL
                                <sub>CR</sub>/125)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">6.54</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>1</sub> &#x00d7; TBW</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.51</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">6.54</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">75.43</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">26.70 %</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">23.90 %</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">18.9%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Crass et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref40">40</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> - &#x03b8;
                                <sub>2</sub> &#x00d7; AGE - &#x03b8;
                                <sub>3</sub> &#x00d7; (SCr)+ &#x03b8;
                                <sub>4</sub> &#x00d7; SEX + &#x03b8;
                                <sub>5</sub> &#x00d7; TBW
                                <sup>0.75</sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                                <break/>&#x03b8;
                                <sub>5</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">8.688
                                <break/>0.075
                                <break/>1.988
                                <break/>1.245
                                <break/>0.073</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>6</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>6</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">73.969</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">5.9</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">74.1</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">39.94%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">33.20%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Pol&#x00e1;skov&#x00e1; et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref41">41</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.83</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>2</sub> &#x00d7; e&#x00d7;p^(&#x03b8;
                                <sub>3</sub> &#x00d7; LBM)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">26.39
                                <break/>0.015</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.83</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">26.39</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.39 (SD)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.39 (SD)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.13 (SD)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="4" valign="middle">
                                <bold>GERIATRICS</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Sanchez et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref43">43</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub>+&#x03b8;
                                <sub>5</sub> &#x00d7; CL
                                <sub>CR</sub> Q = &#x03b8;
                                <sub>4</sub> &#x00d7; TBW</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>5</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.157
                                <break/>0.563
                                <break/>0.111</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = &#x03b8;
                                <sub>2</sub> &#x00d7; TBW V
                                <sub>2</sub> = &#x03b8;
                                <sub>3</sub> &#x00d7; AGE/53.5</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.283
                                <break/>32.2</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = 2.21
                                <break/>Q = 8.12</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 20.71
                                <break/>V
                                <sub>2</sub> = 44.5</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">24.49 %</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = NR
                                <break/>V
                                <sub>2</sub> = 6.8 %</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">24.9%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Zhou et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref45">45</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; (CL
                                <sub>CR</sub>/56.28)^&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.45
                                <break/>0.542</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">154</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.45</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">154</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">17.53%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">34.90%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">6.57%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Zhang et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref44">44</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; (eGFR/80)^&#x03b8;
                                <sub>2</sub> &#x00d7; (1 + &#x03b8;
                                <sub>3</sub> &#x00d7; PCM)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">3.74
                                <break/>1.03
                                <break/>0.41</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">118</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">3.74</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">118</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">44.26%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">54.99%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.184 (log scale)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Ling et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref42">42</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">eGFR by CKD-EPIcys-scr:
                                <break/>CL = 3.79 &#x00d7; (eGFR/ 64.82)^&#x03b8;
                                <sub>1</sub> &#x00d7; (TBW/65)^&#x03b8;
                                <sub>3</sub> eGFR by BIS-2: CL = 3.71 &#x00d7; (eGFR/ 59.53)^&#x03b8;
                                <sub>2</sub> &#x00d7; (TBW/65)^&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1.06
                                <break/>1.11
                                <break/>0.575</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">76.9</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">3.79</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">76.9</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">23.6%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.7</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">23.2%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="4" valign="middle">
                                <bold>CANCER</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Buelga et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref46">46</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; CL
                                <sub>CR</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1.08</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>2</sub> &#x00d7; TBW</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.98</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">5.79</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">63.40</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">28.16%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">37.15%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">3.52</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Okada et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref47">47</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>2</sub> &#x00d7; (CL
                                <sub>CR</sub>/113)^&#x03b8;
                                <sub>6</sub> Q = &#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>6</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">4.25
                                <break/>0.70
                                <break/>1.95</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = &#x03b8;
                                <sub>1</sub> &#x00d7; (TBW/59.4)^&#x03b8;
                                <sub>5</sub>
                                <break/>V
                                <sub>2</sub> = &#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>5</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">39.2
                                <break/>0.78
                                <break/>56.1</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = 4.25
                                <break/>Q = 1.95</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 39.2
                                <break/>V
                                <sub>2</sub> = 56.1</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">25.2%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 14.2%
                                <break/>V
                                <sub>2</sub> = 66.9%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">17.2%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Alqahtani et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref15">15</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; (CL
                                <sub>CR</sub>/99.9)^&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">7.4
                                <break/>0.21</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">45</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">7.4</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">45</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">15.9%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">13.8%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">12.5%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Tsuda et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref48">48</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; (CL
                                <sub>CR</sub> &#x2215; 4.2)^&#x03b8;
                                <sub>2</sub> &#x00d7; &#x0192;qSOFA &#x0192;qSOFA is 1 when qSOFA scores of 0 and it is 0 when qSOFA scores are 1 or greater</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.8
                                <break/>0.8</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = 0.17 &#x00d7; AGE + 0.22 &#x00d7; TBW + 15</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2.8</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">38.40</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">28%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">23.2%</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">
                                <bold>CYSTIC FIBROSIS</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Yellepeddi et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref49">49</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = &#x03b8;
                                <sub>1</sub> &#x00d7; (TBW/52.6)^&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>2</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">5.52
                                <break/>0.5</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V = &#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">31.5</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">5.52</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">31.5</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">23%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.0413 variance</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">
                                <bold>TRAUMA</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Medell&#x00ed;n-Garibay et al.
                                <sup>
                                    <xref ref-type="bibr" rid="ref50">50</xref>
                                </sup>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Furosemide = 0:
                                <break/>CL = &#x03b8;
                                <sub>1</sub> &#x00d7; CL
                                <sub>CR</sub> Furosemide = 1:
                                <break/>CL = &#x03b8;
                                <sub>5</sub> &#x00d7; CL
                                <sub>CR</sub> Q = &#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>1</sub>
                                <break/>&#x03b8;
                                <sub>5</sub>
                                <break/>&#x03b8;
                                <sub>3</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0.49
                                <break/>0.34
                                <break/>0.81</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">If age &gt; 65 years:
                                <break/>V
                                <sub>1</sub> (L/kg) = &#x03b8;
                                <sub>2</sub> &#x00d7; TBW
                                <break/>V
                                <sub>2</sub> (L/kg) = &#x03b8;
                                <sub>4</sub> &#x00d7; TBW If age &#x2264; 65 years:
                                <break/>V
                                <sub>1</sub> (L/kg) = &#x03b8;
                                <sub>6</sub> &#x00d7; TBW</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">&#x03b8;
                                <sub>2</sub>
                                <break/>&#x03b8;
                                <sub>4</sub>
                                <break/>&#x03b8;
                                <sub>6</sub>
                            </td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1.07
                                <break/>5.99
                                <break/>0.74</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">CL = 2.6 (1.85)
                                <break/>Q = 0.81</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 77.4 (53.28)
                                <break/>V
                                <sub>2</sub> = 424.8</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">36.2%</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">V
                                <sub>1</sub> = 37.1%
                                <break/>V
                                <sub>2</sub> = NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">NR</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">19.3%</td>
                        </tr>
                    </tbody>
                </table>
                <table-wrap-foot>
                    <p>

                        <bold>AST</bold> = aspartate aminotransferase (IU/L); 
                        <bold>BIS-2</bold> = Berlin Initiative Study 2; 
                        <bold>BSV</bold> = between-subject variability; 
                        <bold>BUN</bold> = blood urea nitrogen; 
                        <bold>CKD-EPIcys-scr</bold> = Chronic Kidney Disease Epidemiology Collaboration for cystatin C and creatinine; 
                        <bold>CL</bold> = Clearance; 
                        <bold>CL</bold>
                        <sub>

                            <bold>CR</bold>
                        </sub> = creatinine clearance calculated by Cockcroft-Gault formula; 
                        <bold>CL</bold>
                        <sub>

                            <bold>HD</bold>
                        </sub> = hemodialysis clearance; 
                        <bold>CL</bold>
                        <sub>

                            <bold>CRRT</bold>
                        </sub> = CL in patients with continuous renal replacement therapy; CL in patients with hemodialysis; 
                        <bold>CLD</bold>
                        <sub>

                            <bold>BUN</bold>
                        </sub> = in vivo urea dyalisis clearance; 
                        <bold>CLDv</bold> = vancomycin dialysis filter clearance; 
                        <bold>DD</bold> = daily dose (mg/day); 
                        <bold>eGFR</bold> = estimated glomerular filtration rate; 
                        <bold>FIB</bold> = Fibrinogen; 
                        <bold>HD</bold> = hemodialysis; 
                        <bold>IQR</bold> = Interquartile Range; 
                        <bold>KoA</bold> = dialyzer mass transfer-area coefficient; 
                        <bold>LC</bold> = underlying liver cirrhosis; 
                        <bold>LBM</bold> = lean body mass; 
                        <bold>NR</bold> = no reported; 
                        <bold>NEUR</bold> = neurosurgical patient; 
                        <bold>PCM</bold> = post-craniotomy meningitis; 
                        <bold>RV</bold> = residual variability; 
                        <bold>SD</bold> = standard deviation; 
                        <bold>SCr</bold> = serum creatinine; 
                        <bold>STATUS</bold> = Value 1 for patients with gram-positive infections; 
                        <bold>TBW</bold> = total body weight; 
                        <bold>TOXI</bold> = co-administration of nephrotoxic drug; 
                        <bold>TV</bold> = typical value; 
                        <bold>Vc</bold> = central volume; 
                        <bold>Vd</bold> = volume of distribution; 
                        <bold>Vp</bold> = plasma volume; 
                        <bold>Vss</bold> = steady-state volume of distribution.</p>
                </table-wrap-foot>
            </table-wrap>
            <p>To perform an analysis of the TV, the combined means of all studies and also by compartments were calculated; the complete results are found in Supplementary data S2. The TVCL for all studies was 3.02 L/h; by groups the TVCL was 3.76 L/h for the general population, 7.08 L/h for surgical patients, 0.5 L/h for the group with impaired renal function, 5.61 L/h for obese patients, 3.31 L/h for geriatric patients, 4.38 L/h for patients with cancer, 5.52 L/h for cystic fibrosis and 2.6 L/h for trauma patients; when separating the patients without impaired renal function, the TVCL is 4.5 L/h, which differs substantially from that reported in the group with impaired renal function and shows the change with respect to the TVCL of all studies when eliminating those with the lowest clearance.</p>
            <p>The TV of the central distribution volume (TVVc) for all studies was 58.24 L, by groups the TVVc was 42.74 L for the general population, 57.93 L surgical, 64.8 L for the group with impaired renal function, 71.01 L obese, 82.3 L geriatric, 47 L with cancer, 31.5 L with cystic fibrosis and 74.4 L for trauma patients; the TVVc without the obese, geriatric and trauma group is 54.78 L, while in the obese, geriatric and trauma group the TVVc was 78 L. The TVCL for single compartment models was 4.38 L/h and TVV was 61.26 L. The TVCL for two compartment models was 2.63 L/h, TVQ was 8.71 L/h, TVV1 and TVV2 were 38.59 L and 96.97 L respectively.</p>
            <p>Regarding the variability of the TV, the mean between-subject variability coefficients of CL (&#x03c9;CL) were 31.44% (max: 99.20%; min: 5.30%), of the central distribution volume (&#x03c9;Vc) 27.29% (max: 54.99; min: 6.34%) and peripheral (&#x03c9;Vp) 49.45% (max: 72.80%; min: 6.80%); and finally the means of additive (
                <italic toggle="yes">a</italic>) and proportional (
                <italic toggle="yes">b</italic>) errors were 6.67 mg/L (max: 55.00 mg/L; min: 6.34 mg/L) and 27.29% (max: 54.99; min: 0.70%) respectively. The previously mentioned results are summarized in Supplementary data S2.</p>
        </sec>
        <sec id="sec4">
            <title>Discussion</title>
            <p>In the precision dosing, the TDM and development of PopPK within the MIPD is relevant to improve efficacy and/or lower toxicity in special populations with high variability, like pediatrics, elderly, those with renal or hepatic impairment and comedicated patients. The translation of this approach personalized medicine requires the implementation of new dosing scenarios, new working paradigms and clinical pharmacology experts and researchers, that are not limited only to the academic area.
                <sup>
                    <xref ref-type="bibr" rid="ref51">51</xref>
                </sup>
            </p>
            <p>NONMEM (ICON, Dublin, Ireland), Monolix (Lixoft, Paris, France) and Phoenix NLME (Certara, Princeton, NJ) are the most widely used nonlinear mixed effects modeling (NLMEM) tools in pharmacometrics. They are commercial offerings with fees substantial licensing costs, and while all have programs aimed at reducing or eliminating licensing costs in educational institutions or low-income countries, the administrative hurdles and associated delays in availability can be cumbersome when conducting analysis and training students and researchers to use these tools in resource-limited settings. Implementation of open-source software based on R and the nlmixr package may be a credible and capable alternative to commercial PK/PD modeling software to fit compartmental of pharmacokinetic/pharmacodynamic (PK/PD) models described by ordinary differential equations (ODEs). Parameter estimation algorithms implemented in nlmixr currently include relatively mature implementations of NLMEM, SAEM, and first-order, first-order with interaction, FOCE, and FOCEI.
                <sup>
                    <xref ref-type="bibr" rid="ref52">52</xref>
                </sup>
            </p>
            <p>About the development of PopPK models we can observe for vancomycin it is expected that CL
                <sub>CR</sub> would be the most important covariable in most models and could affect the CL and the prediction of serum vancomycin concentration, it is because vancomycin is excreted 80% to 90% as an unchanged drug in urine
                <sup>
                    <xref ref-type="bibr" rid="ref19">19</xref>
                </sup>; conventionally, the eGFR is calculated by the Cockroft-Gault equation, however, the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), Modification of Diet in Renal Disease (MDRD) and Berlin Initiative Study 2 (BIS-2) equations has been shown to be more accurate, especially in youngest.
                <sup>
                    <xref ref-type="bibr" rid="ref53">53</xref>
                </sup> This is because, although the Cockcroft-Gault equation is widely used in pharmacokinetic studies and drug dosing adjustments, it has several limitations. It was developed in a specific population, primarily adult males, which limits its applicability to other groups, such as elderly individuals, patients with altered body composition (e.g., obesity, cachexia), or critically ill patients. Additionally, since it relies on serum creatinine levels, it is influenced by factors such as muscle mass, diet, and hydration status, potentially leading to inaccurate estimations of renal function. The equation also lacks standardization across different creatinine assay methods, and its accuracy diminishes in patients with very low or highly fluctuating glomerular filtration rates (GFR), such as those with acute kidney injury (AKI). Moreover, the use of actual body weight can introduce further errors, particularly in patients with obesity or fluid overload. Despite these limitations, the Cockcroft-Gault equation remains widely used due to its historical application in drug dosing guidelines and its inclusion in many pharmacokinetic models.</p>
            <p>Ling et al. used to covariate the model CKD-EPIcys and BIS-2 eGFR with specific equations for each one.
                <sup>
                    <xref ref-type="bibr" rid="ref42">42</xref>
                </sup> Beyond that, models have always been compared to the CL
                <sub>CR</sub>, including the studies like Tanaka et al. which uses cystatin C, those who consider that this may be more accurate and sensitive than creatinine for calculating eGFR, suggesting that it could be a good predictive marker of CL and vancomycin concentrations.
                <sup>
                    <xref ref-type="bibr" rid="ref23">23</xref>
                </sup>
            </p>
            <p>Great difference was found in TV estimates, the population with significantly higher TVCL and TVV are obese and surgical patients; in both, this finding in TVCL are explained by the augmented renal clearance (ARC) in early stage of the surgical approach or in obese by the compensatory vasodilation of the afferent arteriole,
                <sup>
                    <xref ref-type="bibr" rid="ref54">54</xref>
                </sup> also in neurological patients the brain lesions and the loss of autoregulation induced by brain injury may impair the kidney autoregulatory process
                <sup>
                    <xref ref-type="bibr" rid="ref29">29</xref>
                </sup>; in the obese population because the volume of distribution is linked to weight and also to the constants of CL
                <sub>CR</sub>, it is expected that both the TVCL and the TVV increase.
                <sup>
                    <xref ref-type="bibr" rid="ref39">39</xref>
                </sup> The trauma and elderly have also the highest TVV (central and peripheral) but lowest TVCL; Variability in trauma patients CL is due to the fact that the elimination of vancomycin depending on tubular secretion and the concomitant administration of other drugs, such as furosemide
                <sup>
                    <xref ref-type="bibr" rid="ref50">50</xref>
                </sup>; the renal function of the elderly gradually decreases with age and the larger volume of distribution may be by the changes in the peripheral circulation usually due to poor nutrition, hypoalbuminemia and internal environmental disorders such as hypokalemia, hyponatremia and metabolic acidosis that increased tissue affinity for vancomycin, and the TVV is high because they are attached to the weight.
                <sup>
                    <xref ref-type="bibr" rid="ref45">45</xref>
                </sup> In patients with impairment kidney function the heterogenicity of the TVCL it is due to changes in the central compartment generated by renal effect of the vancomycin, dialysis and changes in the ultrafiltration rate of each session, for this reason eGFR estimated by Cockroft-Gault equation is not a reliable marker of renal function.
                <sup>
                    <xref ref-type="bibr" rid="ref33">33</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref36">36</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref37">37</xref>
                </sup> Patients with above-the-mean vancomycin clearance and volume of distribution typically exhibit pharmacokinetic profiles associated with increased drug elimination and expanded drug distribution. Several factors may contribute to these elevated parameters, including younger age, preserved or augmented renal function, higher body weight, and conditions associated with hyperdynamic circulation, such as sepsis or burns. Higher clearance rates may result in subtherapeutic vancomycin concentrations, potentially reducing efficacy and increasing the risk of treatment failure, particularly in infections caused by less susceptible pathogens. Similarly, an increased volume of distribution may lead to lower peak concentrations, which could impact the drug&#x2019;s time-dependent antibacterial activity. Given these considerations, patients with above-the-mean clearance and volume of distribution may require individualized dosing strategies, such as higher initial doses, more frequent administration, or therapeutic drug monitoring to ensure optimal target attainment while minimizing the risk of underexposure.
                <sup>
                    <xref ref-type="bibr" rid="ref55">55</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref57">57</xref>
                </sup>
            </p>
            <p>To end when we look at the variability of the models is striking that for the patients undergoing allogeneic transplantation, the models developed indicate a high variability due to high between-subject variability and the difficulty of maintaining the therapeutic range, due to the characteristics of these patients with extremely low hematocrit levels, increased intravascular volume, and increased renal clearance.
                <sup>
                    <xref ref-type="bibr" rid="ref46">46</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref48">48</xref>
                </sup> It is important to note that this review had several limitations. Some of the papers do not specify the clinical and pathological characteristics of the study subjects. The creatinine clearance formulas are different in every article making necessary the classification of every subpopulation before applying the model, the units of measure and the population have great variability. That is the main reason why the comparisons presented are indirect and the generalization of the data that we show must be read carefully.</p>
        </sec>
        <sec id="sec5">
            <title>Conclusions and recommendations for future research</title>
            <p>This scoping review highlights the principal information of different PopPK models, which showed heterogeneity in the parameters and methods of analysis and evaluation, even if these methods can be used to guide the dosing regimen in different subpopulations, it is imperative to conduct experiments with local samples to define the best fit in the different subpopulation.</p>
        </sec>
        <sec id="sec6">
            <title>Data availability</title>
            <sec id="sec7">
                <title>Underlying data</title>
                <p>All data underlying the results are available as part of the article and no additional source data are required.</p>
            </sec>
            <sec id="sec8">
                <title>Extended data</title>
                <p>Zenodo: Scoping review on Population pharmacokinetics of vancomycin in non-critically ill. 
                    <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.14876777">https://doi.org/10.5281/zenodo.14876777</ext-link>
                    <sup>
                        <xref ref-type="bibr" rid="ref58">58</xref>
                    </sup>
                </p>
                <p>This project contains the following underlying data:
                    <list list-type="bullet">
                        <list-item>
                            <label>&#x2022;</label>
                            <p>PkPop Vanco_non critical patients - Extended data E1 PRISMA-ScR checklist.docx</p>
                        </list-item>
                        <list-item>
                            <label>&#x2022;</label>
                            <p>PkPop Vanco_non critical ill patients - Extended data E2 Additional results tables.pdf</p>
                        </list-item>
                        <list-item>
                            <label>&#x2022;</label>
                            <p>LICENSE.txt- - Supplementary data S2: Additional results tables.pdf</p>
                        </list-item>
                        <list-item>
                            <label>&#x2022;</label>
                            <p>LICENSE.txt</p>
                        </list-item>
                    </list>
                </p>
                <p>Data are available under the terms of the 
                    <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link> (CC-BY 4.0).</p>
            </sec>
        </sec>
    </body>
    <back>
        <ack>
            <title>Acknowledgements</title>
            <p>We would like to thank the Universidad de La Sabana.</p>
        </ack>
        <ref-list>
            <title>References</title>
            <ref id="ref1">
                <label>1</label>
                <mixed-citation publication-type="data">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Levine</surname>
                            <given-names>DP</given-names>
                        </name>
</person-group>:
                    <article-title>Vancomycin: a history.</article-title>
                    <source>

                        <italic toggle="yes">Clin. Infect. Dis.</italic>
</source>
                    <year>2006 Jan</year>;<volume>42 Suppl 1</volume>:<fpage>S5</fpage>&#x2013;<lpage>12</lpage>.
                    <pub-id pub-id-type="pmid">16323120</pub-id>
                    <pub-id pub-id-type="doi">10.1086/491709</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref2">
                <label>2</label>
                <mixed-citation publication-type="book">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Patel</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Preuss</surname>
                            <given-names>CV</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bernice</surname>
                            <given-names>F</given-names>
                        </name>
</person-group>:
                    <chapter-title>Vancomycin.</chapter-title>
                    <source>

                        <italic toggle="yes">StatPearls.</italic>
</source>
                    <publisher-loc>Treasure Island (FL)</publisher-loc>:
                    <publisher-name>StatPearls Publishing Copyright &#x00a9; 2021, StatPearls Publishing LLC</publisher-name>;<year>2021</year>.</mixed-citation>
            </ref>
            <ref id="ref3">
                <label>3</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Farber</surname>
                            <given-names>BF</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Moellering</surname>
                            <given-names>RC</given-names>
                            <suffix>Jr</suffix>
                        </name>
</person-group>:
                    <article-title>Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981.</article-title>
                    <source>

                        <italic toggle="yes">Antimicrob. Agents Chemother.</italic>
</source>
                    <year>1983 Jan</year>;<volume>23</volume>(<issue>1</issue>):<fpage>138</fpage>&#x2013;<lpage>141</lpage>.
                    <pub-id pub-id-type="pmid">6219616</pub-id>
                    <pub-id pub-id-type="doi">10.1128/AAC.23.1.138</pub-id>
                    <pub-id pub-id-type="pmcid">PMC184631</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref4">
                <label>4</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Hal</surname>
                            <given-names>SJ</given-names>
                            <prefix>van</prefix>
                        </name>

                        <name name-style="western">
                            <surname>Paterson</surname>
                            <given-names>DL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lodise</surname>
                            <given-names>TP</given-names>
                        </name>
</person-group>:
                    <article-title>Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter.</article-title>
                    <source>

                        <italic toggle="yes">Antimicrob. Agents Chemother.</italic>
</source>
                    <year>2013 Feb</year>;<volume>57</volume>(<issue>2</issue>):<fpage>734</fpage>&#x2013;<lpage>744</lpage>. Epub 20121119.
                    <pub-id pub-id-type="pmid">23165462</pub-id>
                    <pub-id pub-id-type="doi">10.1128/AAC.01568-12</pub-id>
                    <pub-id pub-id-type="pmcid">PMC3553731</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref5">
                <label>5</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Rybak</surname>
                            <given-names>MJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Le</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lodise</surname>
                            <given-names>TP</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.</article-title>
                    <source>

                        <italic toggle="yes">Am. J. Health Syst. Pharm.</italic>
</source>
                    <year>2020</year>;<volume>77</volume>(<issue>11</issue>):<fpage>835</fpage>&#x2013;<lpage>864</lpage>.
                    <pub-id pub-id-type="pmid">32191793</pub-id>
                    <pub-id pub-id-type="doi">10.1093/ajhp/zxaa036</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref6">
                <label>6</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Hall</surname>
                            <given-names>NM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Brown</surname>
                            <given-names>ML</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Edwards</surname>
                            <given-names>WS</given-names>
                        </name>

                        <etal/>
</person-group>.:
                    <article-title>Model-Informed Precision Dosing Improves Outcomes in Patients Receiving Vancomycin for Gram-Positive Infections.</article-title>
                    <source>

                        <italic toggle="yes">Open Forum. Infect. Dis.</italic>
                    </source>
                    <year>2024 Jan</year>;<volume>11</volume>(<issue>1</issue>): ofae002.
                    <pub-id pub-id-type="pmid">38250202</pub-id>
                    <pub-id pub-id-type="doi">10.1093/ofid/ofae002</pub-id>
                    <pub-id pub-id-type="pmcid">PMC10799298</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref7">
                <label>7</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Tyson</surname>
                            <given-names>RJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Park</surname>
                            <given-names>CC</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Powell</surname>
                            <given-names>JR</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables.</article-title>
                    <source>

                        <italic toggle="yes">Front. Pharmacol.</italic>
                    </source>
                    <year>2020</year>2020-April-11;<volume>11</volume>.
                    <pub-id pub-id-type="doi">10.3389/fphar.2020.00420</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref8">
                <label>8</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Umpi&#x00e9;rrez</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Guevara</surname>
                            <given-names>N</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ibarra</surname>
                            <given-names>M</given-names>
                        </name>

                        <etal/>
</person-group>.:
                    <article-title>Development of a Population Pharmacokinetic Model for Cyclosporine from Therapeutic Drug Monitoring Data.</article-title>
                    <source>

                        <italic toggle="yes">Biomed. Res. Int.</italic>
                    </source>
                    <year>2021</year>;<volume>2021</volume>:<fpage>3108749</fpage>.
                    <pub-id pub-id-type="pmid">33928146</pub-id>
                    <pub-id pub-id-type="pmcid">PMC8052134</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref9">
                <label>9</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Chen</surname>
                            <given-names>WJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhou</surname>
                            <given-names>TY</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lu</surname>
                            <given-names>W</given-names>
                        </name>
</person-group>:
                    <article-title>Population pharmacokinetics and its application in new drug research.</article-title>
                    <source>

                        <italic toggle="yes">Yao Xue Xue Bao.</italic>
</source>
                    <year>2017 Mar</year>;<volume>52</volume>(<issue>3</issue>):<fpage>371</fpage>&#x2013;<lpage>377</lpage>.
                    <pub-id pub-id-type="pmid">29979556</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref10">
                <label>10</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Dave</surname>
                            <given-names>V</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Yadav</surname>
                            <given-names>RB</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Yadav</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>A Critique of Computer Simulation Software's Used in Pharmacokinetics and Pharmacodynamics Analysis.</article-title>
                    <source>

                        <italic toggle="yes">Curr. Clin. Pharmacol.</italic>
</source>
                    <year>2018</year>;<volume>13</volume>(<issue>4</issue>):<fpage>216</fpage>&#x2013;<lpage>235</lpage>.
                    <pub-id pub-id-type="pmid">30360723</pub-id>
                    <pub-id pub-id-type="doi">10.2174/1574884713666181025144845</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref11">
                <label>11</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Peters</surname>
                            <given-names>MDJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Marnie</surname>
                            <given-names>C</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Tricco</surname>
                            <given-names>AC</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Updated methodological guidance for the conduct of scoping reviews.</article-title>
                    <source>

                        <italic toggle="yes">JBI Evid. Synth.</italic>
                    </source>
                    <year>2020 Oct</year>;<volume>18</volume>(<issue>10</issue>):<fpage>2119</fpage>&#x2013;<lpage>26</lpage>.
                    <pub-id pub-id-type="pmid">33038124</pub-id>
                    <pub-id pub-id-type="doi">10.11124/JBIES-20-00167</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref12">
                <label>12</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Tricco</surname>
                            <given-names>AC</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lillie</surname>
                            <given-names>E</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zarin</surname>
                            <given-names>W</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation.</article-title>
                    <source>

                        <italic toggle="yes">Ann. Intern. Med.</italic>
</source>
                    <year>2018 Oct 2</year>;<volume>169</volume>(<issue>7</issue>):<fpage>467</fpage>&#x2013;<lpage>473</lpage>. Epub 20180904.
                    <pub-id pub-id-type="pmid">30178033</pub-id>
                    <pub-id pub-id-type="doi">10.7326/M18-0850</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref13">
                <label>13</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ouzzani</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Hammady</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Fedorowicz</surname>
                            <given-names>Z</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Rayyan-a web and mobile app for systematic reviews.</article-title>
                    <source>

                        <italic toggle="yes">Syst. Rev.</italic>
</source>
                    <year>2016 Dec 5</year>;<volume>5</volume>(<issue>1</issue>):<fpage>210</fpage>. Epub 20161205.
                    <pub-id pub-id-type="pmid">27919275</pub-id>
                    <pub-id pub-id-type="doi">10.1186/s13643-016-0384-4</pub-id>
                    <pub-id pub-id-type="pmcid">PMC5139140</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref14">
                <label>14</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Aljutayli</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Marsot</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Nekka</surname>
                            <given-names>F</given-names>
                        </name>
</person-group>.:
                    <article-title>An Update on Population Pharmacokinetic Analyses of Vancomycin. Part I: In Adults. </article-title>
                    <source>
                        <italic toggle="yes">Clin. Pharmacokinet.</italic>
                    </source>
                    <year>2020 Jun</year>;<volume>59</volume>(<issue>6</issue>):<fpage>671</fpage>&#x2013;<lpage>698</lpage>. Epub 2020/02/06.
                    <pub-id pub-id-type="pmid">32020531</pub-id>
                    <pub-id pub-id-type="doi">10.1007/s40262-020-00866-2</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref15">
                <label>15</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Alqahtani</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Almatrafi</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bin Aydan</surname>
                            <given-names>N</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Optimization of Vancomycin Dosing Regimen in Cancer Patients using Pharmacokinetic/Pharmacodynamic Modeling.</article-title>
                    <source>

                        <italic toggle="yes">Pharmacotherapy.</italic>
</source>
                    <year>2020 Dec</year>;<volume>40</volume>(<issue>12</issue>):<fpage>1192</fpage>&#x2013;<lpage>1200</lpage>. Epub 20201123.
                    <pub-id pub-id-type="pmid">33084059</pub-id>
                    <pub-id pub-id-type="doi">10.1002/phar.2475</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref16">
                <label>16</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Bae</surname>
                            <given-names>SH</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Yim</surname>
                            <given-names>D-S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>H</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Application of Pharmacometrics in Pharmacotherapy: Open-Source Software for Vancomycin Therapeutic Drug Management.</article-title>
                    <source>

                        <italic toggle="yes">Pharmaceutics.</italic>
</source>
                    <year>2019</year>;<volume>11</volume>(<issue>5</issue>):<fpage>224</fpage>.
                    <pub-id pub-id-type="pmid">31075931</pub-id>
                    <pub-id pub-id-type="doi">10.3390/pharmaceutics11050224</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6572512</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref17">
                <label>17</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Chung</surname>
                            <given-names>JY</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Jin</surname>
                            <given-names>SJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Yoon</surname>
                            <given-names>JH</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations.</article-title>
                    <source>

                        <italic toggle="yes">J. Korean Med. Sci.</italic>
                    </source>
                    <year>2013 Jan</year>;<volume>28</volume>(<issue>1</issue>):<fpage>48</fpage>&#x2013;<lpage>54</lpage>. Epub 2013/01/24.
                    <pub-id pub-id-type="pmid">23341711</pub-id>
                    <pub-id pub-id-type="pmcid">PMC3546104</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref18">
                <label>18</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Deng</surname>
                            <given-names>C</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Liu</surname>
                            <given-names>T</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhou</surname>
                            <given-names>T</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis.</article-title>
                    <source>

                        <italic toggle="yes">Int. J. Clin. Pharmacol. Ther.</italic>
</source>
                    <year>2013 May</year>;<volume>51</volume>(<issue>5</issue>):<fpage>407</fpage>&#x2013;<lpage>415</lpage>.
                    <pub-id pub-id-type="pmid">23458230</pub-id>
                    <pub-id pub-id-type="doi">10.5414/CP201842</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref19">
                <label>19</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ji</surname>
                            <given-names>XW</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ji</surname>
                            <given-names>SM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>He</surname>
                            <given-names>XR</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients.</article-title>
                    <source>

                        <italic toggle="yes">Acta Pharmacol. Sin.</italic>
</source>
                    <year>2018 Feb</year>;<volume>39</volume>(<issue>2</issue>):<fpage>286</fpage>&#x2013;<lpage>293</lpage>. Epub 20170824.
                    <pub-id pub-id-type="pmid">28836582</pub-id>
                    <pub-id pub-id-type="doi">10.1038/aps.2017.57</pub-id>
                    <pub-id pub-id-type="pmcid">PMC5800467</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref20">
                <label>20</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Lim</surname>
                            <given-names>HS</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Chong</surname>
                            <given-names>YP</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Noh</surname>
                            <given-names>YH</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.</article-title>
                    <source>

                        <italic toggle="yes">J. Clin. Pharm. Ther.</italic>
                    </source>
                    <year>2014 Apr</year>;<volume>39</volume>(<issue>2</issue>):<fpage>196</fpage>&#x2013;<lpage>203</lpage>. Epub 2014/01/17.
                    <pub-id pub-id-type="pmid">24428720</pub-id>
                    <pub-id pub-id-type="doi">10.1111/jcpt.12123</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref21">
                <label>21</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Liu</surname>
                            <given-names>TT</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pang</surname>
                            <given-names>HM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Jing</surname>
                            <given-names>L</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>A population pharmacokinetic model of vancomycin for dose individualization based on serum cystatin C as a marker of renal function.</article-title>
                    <source>

                        <italic toggle="yes">J. Pharm. Pharmacol.</italic>
                    </source>
                    <year>2019 Jun</year>;<volume>71</volume>(<issue>6</issue>):<fpage>945</fpage>&#x2013;<lpage>955</lpage>. Epub 2019/03/16.
                    <pub-id pub-id-type="pmid">30873627</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref22">
                <label>22</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Purwonugroho</surname>
                            <given-names>TA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Chulavatnatol</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Preechagoon</surname>
                            <given-names>Y</given-names>
                        </name>

                        <etal/>
</person-group>.:
                    <article-title>Population pharmacokinetics of vancomycin in Thai patients.</article-title>
                    <source>

                        <italic toggle="yes">ScientificWorldJournal.</italic>
                    </source>
                    <year>2012</year>;<volume>2012</volume>:<fpage>762649</fpage>. Epub 2012/05/02.
                    <pub-id pub-id-type="pmid">22547995</pub-id>
                    <pub-id pub-id-type="doi">10.1100/2012/762649</pub-id>
                    <pub-id pub-id-type="pmcid">PMC3322481</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref23">
                <label>23</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Tanaka</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Aiba</surname>
                            <given-names>T</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Otsuka</surname>
                            <given-names>T</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function.</article-title>
                    <source>

                        <italic toggle="yes">Antimicrob. Agents Chemother.</italic>
</source>
                    <year>2010 Feb</year>;<volume>54</volume>(<issue>2</issue>):<fpage>778</fpage>&#x2013;<lpage>782</lpage>. Epub 20091123.
                    <pub-id pub-id-type="pmid">19933799</pub-id>
                    <pub-id pub-id-type="pmcid">PMC2812172</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref24">
                <label>24</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Usman</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Fobker</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Hempel</surname>
                            <given-names>G</given-names>
                        </name>
</person-group>.:
                    <article-title>Investigation of the age dependency of vancomycin clearance by population pharmacokinetic modeling.</article-title>
                    <source>

                        <italic toggle="yes">Int. J. Clin. Pharmacol. Ther.</italic>
                    </source>
                    <year>2018 Feb</year>;<volume>56</volume>(<issue>2</issue>):<fpage>56</fpage>&#x2013;<lpage>63</lpage>. Epub 2018/01/11.
                    <pub-id pub-id-type="pmid">29319495</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref25">
                <label>25</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Yamamoto</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kuzuya</surname>
                            <given-names>T</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Baba</surname>
                            <given-names>H</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type.</article-title>
                    <source>

                        <italic toggle="yes">J. Clin. Pharm. Ther.</italic>
</source>
                    <year>2009 Aug</year>;<volume>34</volume>(<issue>4</issue>):<fpage>473</fpage>&#x2013;<lpage>483</lpage>.
                    <pub-id pub-id-type="pmid">19583681</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref26">
                <label>26</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Yasuhara</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Iga</surname>
                            <given-names>T</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zenda</surname>
                            <given-names>H</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Population pharmacokinetics of vancomycin in Japanese adult patients.</article-title>
                    <source>

                        <italic toggle="yes">Ther. Drug Monit.</italic>
</source>
                    <year>1998 Apr</year>;<volume>20</volume>(<issue>2</issue>):<fpage>139</fpage>&#x2013;<lpage>148</lpage>.
                    <pub-id pub-id-type="pmid">9558127</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref27">
                <label>27</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Alqahtani</surname>
                            <given-names>SA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Alsultan</surname>
                            <given-names>AS</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Alqattan</surname>
                            <given-names>HM</given-names>
                        </name>

                        <etal/>
</person-group>.:
                    <article-title>Population Pharmacokinetic Model for Vancomycin Used in Open Heart Surgery: Model-Based Evaluation of Standard Dosing Regimens.</article-title>
                    <source>

                        <italic toggle="yes">Antimicrob. Agents Chemother.</italic>
                    </source>
                    <year>2018 Jul</year>;<volume>62</volume>(<issue>7</issue>). Epub 2018/04/25.
                    <pub-id pub-id-type="pmid">29686154</pub-id>
                    <pub-id pub-id-type="doi">10.1128/AAC.00088-18</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6021682</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref28">
                <label>28</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Jing</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Liu</surname>
                            <given-names>TT</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Guo</surname>
                            <given-names>Q</given-names>
                        </name>

                        <etal/>
</person-group>.:
                    <article-title>Development and comparison of population pharmacokinetic models of vancomycin in neurosurgical patients based on two different renal function markers.</article-title>
                    <source>

                        <italic toggle="yes">J .Clin. Pharm. Ther.</italic>
                    </source>
                    <year>2020 Feb</year>;<volume>45</volume>(<issue>1</issue>):<fpage>88</fpage>&#x2013;<lpage>96</lpage>. Epub 2019/08/30.
                    <pub-id pub-id-type="pmid">31463971</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref29">
                <label>29</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Kim</surname>
                            <given-names>AJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>JY</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Choi</surname>
                            <given-names>SA</given-names>
                        </name>

                        <etal/>
</person-group>.:
                    <article-title>Comparison of the pharmacokinetics of vancomycin in neurosurgical and non-neurosurgical patients.</article-title>
                    <source>

                        <italic toggle="yes">Int. J. Antimicrob. Agents. </italic>
                    </source>
                    <year>2016 Oct</year>;<volume>48</volume>(<issue>4</issue>):<fpage>381</fpage>&#x2013;<lpage>387</lpage>. Epub 2016/08/23.
                    <pub-id pub-id-type="pmid">27546217</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref30">
                <label>30</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Munir</surname>
                            <given-names>MM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Rasheed</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Khokhar</surname>
                            <given-names>MI</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Dose Tailoring of Vancomycin Through Population Pharmacokinetic Modeling Among Surgical Patients in Pakistan.</article-title>
                    <source>

                        <italic toggle="yes">Front. Pharmacol.</italic>
                    </source>
                    <year>2021</year>;<volume>12</volume>: 721819. Epub 2021/12/04.
                    <pub-id pub-id-type="pmid">34858169</pub-id>
                    <pub-id pub-id-type="pmcid">PMC8632000</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref31">
                <label>31</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Wei</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhang</surname>
                            <given-names>D</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhao</surname>
                            <given-names>Z</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Population pharmacokinetic model of vancomycin in postoperative neurosurgical patients.</article-title>
                    <source>

                        <italic toggle="yes">Front. Pharmacol.</italic>
                    </source>
                    <year>2022</year>;<volume>13</volume>:<fpage>1005791</fpage>. Epub 2022/10/14.
                    <pub-id pub-id-type="pmid">36225566</pub-id>
                    <pub-id pub-id-type="pmcid">PMC9548544</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref32">
                <label>32</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ahmed</surname>
                            <given-names>KA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ibrahim</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Gonzalez</surname>
                            <given-names>D</given-names>
                        </name>

                        <etal/>
</person-group>.:
                    <article-title>Population Pharmacokinetics and Model-Based Dose Optimization of Vancomycin in Sudanese Adult Patients with Renal Impairment.</article-title>
                    <source>

                        <italic toggle="yes">Drug Des. Devel. Ther.</italic>
                    </source>
                    <year>2024</year>;<volume>18</volume>:<fpage>81</fpage>&#x2013;<lpage>95</lpage>. Epub 2024/01/23.
                    <pub-id pub-id-type="pmid">38260090</pub-id>
                    <pub-id pub-id-type="doi">10.2147/DDDT.S432439</pub-id>
                    <pub-id pub-id-type="pmcid">PMC10800288</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref33">
                <label>33</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Kim</surname>
                            <given-names>DJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>DH</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ahn</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>A new population pharmacokinetic model for vancomycin in patients with variable renal function: Therapeutic drug monitoring based on extended covariate model using CKD-EPI estimation.</article-title>
                    <source>

                        <italic toggle="yes">J. Clin. Pharm. Ther.</italic>
                    </source>
                    <year>2019 Oct</year>;<volume>44</volume>(<issue>5</issue>):<fpage>750</fpage>&#x2013;<lpage>759</lpage>. Epub 20190622.
                    <pub-id pub-id-type="pmid">31228353</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref34">
                <label>34</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ma</surname>
                            <given-names>KF</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Liu</surname>
                            <given-names>YX</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Jiao</surname>
                            <given-names>Z</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization.</article-title>
                    <source>

                        <italic toggle="yes">Front. Pharmacol.</italic>
                    </source>
                    <year>2020</year>;<volume>11</volume>: 563967. Epub 20201006.
                    <pub-id pub-id-type="pmid">33117163</pub-id>
                    <pub-id pub-id-type="pmcid">PMC7573825</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref35">
                <label>35</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Oda</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Jono</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Saito</surname>
                            <given-names>H</given-names>
                        </name>
</person-group>:
                    <article-title>Model-Informed Precision Dosing of Vancomycin in Adult Patients Undergoing Hemodialysis.</article-title>
                    <source>

                        <italic toggle="yes">Antimicrob. Agents Chemother.</italic>
</source>
                    <year>2023</year>;<volume>67</volume>(<issue>6</issue>):<fpage>e00089</fpage>&#x2013;<lpage>e00023</lpage>.
                    <pub-id pub-id-type="doi">10.1128/aac.00089-23</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref36">
                <label>36</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Pai</surname>
                            <given-names>MP</given-names>
                        </name>

                        <name name-style="western">
                            <surname>DeBacker</surname>
                            <given-names>KC</given-names>
                        </name>
</person-group>.:
                    <article-title>Modeling Kinetic Glomerular Filtration Rate in Adults with Stable and Unstable Kidney Function: Vancomycin as the Motivating Example.</article-title>
                    <source>

                        <italic toggle="yes">Pharmacotherapy.</italic>
                    </source>
                    <year>2020 Sep</year>;<volume>40</volume>(<issue>9</issue>):<fpage>872</fpage>&#x2013;<lpage>879</lpage>. Epub 20200804.
                    <pub-id pub-id-type="pmid">32640054</pub-id>
                    <pub-id pub-id-type="doi">10.1002/phar.2442</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref37">
                <label>37</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Schaedeli</surname>
                            <given-names>F</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Uehlinger</surname>
                            <given-names>DE</given-names>
                        </name>
</person-group>:
                    <article-title>Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis.</article-title>
                    <source>

                        <italic toggle="yes">Clin. Pharmacol. Ther.</italic>
</source>
                    <year>1998 Jan</year>;<volume>63</volume>(<issue>1</issue>):<fpage>26</fpage>&#x2013;<lpage>38</lpage>.
                    <pub-id pub-id-type="pmid">9465839</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref38">
                <label>38</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Zaric</surname>
                            <given-names>RZ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Milovanovic</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Rosic</surname>
                            <given-names>N</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Pharmacokinetics of Vancomycin in Patients with Different Renal Function Levels.</article-title>
                    <source>

                        <italic toggle="yes">Open Med (Wars).</italic>
                    </source>
                    <year>2018</year>;<volume>13</volume>:<fpage>512</fpage>&#x2013;<lpage>519</lpage>. Epub 2018/11/15.
                    <pub-id pub-id-type="pmid">30426090</pub-id>
                    <pub-id pub-id-type="doi">10.1515/med-2018-0068</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6227840</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref39">
                <label>39</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Adane</surname>
                            <given-names>ED</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Herald</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Koura</surname>
                            <given-names>F</given-names>
                        </name>
</person-group>.:
                    <article-title>Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.</article-title>
                    <source>

                        <italic toggle="yes">Pharmacotherapy.</italic>
                    </source>
                    <year>2015 Feb</year>;<volume>35</volume>(<issue>2</issue>):<fpage>127</fpage>&#x2013;<lpage>139</lpage>. Epub 20150203.
                    <pub-id pub-id-type="pmid">25644478</pub-id>
                    <pub-id pub-id-type="doi">10.1002/phar.1531</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref40">
                <label>40</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Crass</surname>
                            <given-names>RL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dunn</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Hong</surname>
                            <given-names>J</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Dosing vancomycin in the super obese: less is more.</article-title>
                    <source>

                        <italic toggle="yes">J. Antimicrob. Chemother.</italic>
                    </source>
                    <year>2018 Nov 1</year>;<volume>73</volume>(<issue>11</issue>):<fpage>3081</fpage>&#x2013;<lpage>3086</lpage>. Epub 2018/09/12.
                    <pub-id pub-id-type="pmid">30203073</pub-id>
                    <pub-id pub-id-type="doi">10.1093/jac/dky310</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref41">
                <label>41</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Pol&#x00e1;&#x0161;kov&#x00e1;</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Hartinger</surname>
                            <given-names>JM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Mur&#x00ed;nov&#x00e1;</surname>
                            <given-names>I</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Vancomycin loading dose individualization in a population of obese patients undergoing haemodialysis based on population pharmacokinetic model.</article-title>
                    <source>

                        <italic toggle="yes">J. Chemother.</italic>
</source>
                    <year>2024 Jun 17</year>:<fpage>1</fpage>&#x2013;<lpage>9</lpage>. Epub 2024/06/18.
                    <pub-id pub-id-type="pmid">38887026</pub-id>
                    <pub-id pub-id-type="doi">10.1080/1120009X.2024.2367937</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref42">
                <label>42</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ling</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Yang</surname>
                            <given-names>X</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dong</surname>
                            <given-names>L</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Utility of cystatin C and serum creatinine-based glomerular filtration rate equations in predicting vancomycin clearance: A population pharmacokinetics analysis in elderly Chinese patients.</article-title>
                    <source>

                        <italic toggle="yes">Biopharm. Drug Dispos.</italic>
</source>
                    <year>2024 Feb</year>;<volume>45</volume>(<issue>1</issue>):<fpage>58</fpage>&#x2013;<lpage>68</lpage>. Epub 2024/02/06.
                    <pub-id pub-id-type="pmid">38319316</pub-id>
                    <pub-id pub-id-type="doi">10.1002/bdd.2383</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref43">
                <label>43</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>S&#x00e1;nchez</surname>
                            <given-names>JL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dominguez</surname>
                            <given-names>AR</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lane</surname>
                            <given-names>JR</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Population pharmacokinetics of vancomycin in adult and geriatric patients: Comparison of eleven approaches.</article-title>
                    <source>

                        <italic toggle="yes">Int. J. Clin. Pharmacol. Ther.</italic>
</source>
                    <year>2010</year>;<volume>48</volume>(<issue>8</issue>):<fpage>525</fpage>&#x2013;<lpage>533</lpage>.
                    <pub-id pub-id-type="pmid">20650044</pub-id>
                    <pub-id pub-id-type="doi">10.5414/CPP48525</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref44">
                <label>44</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Zhang</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lin</surname>
                            <given-names>W</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wu</surname>
                            <given-names>W</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Population pharmacokinetics of vancomycin in Chinese elderly patients and its application for dose individualisation.</article-title>
                    <source>

                        <italic toggle="yes">J. Chin. Pharm. Sci.</italic>
</source>
                    <year>2020</year>;<volume>29</volume>(<issue>4</issue>):<fpage>260</fpage>&#x2013;<lpage>271</lpage>.
                    <pub-id pub-id-type="doi">10.5246/jcps.2020.04.025</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref45">
                <label>45</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Zhou</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Gao</surname>
                            <given-names>F</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Chen</surname>
                            <given-names>C</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Development of a Population Pharmacokinetic Model of Vancomycin and its Application in Chinese Geriatric Patients with Pulmonary Infections.</article-title>
                    <source>

                        <italic toggle="yes">Eur. J. Drug Metab. Pharmacokinet.</italic>
</source>
                    <year>2019 Jun</year>;<volume>44</volume>(<issue>3</issue>):<fpage>361</fpage>&#x2013;<lpage>370</lpage>.
                    <pub-id pub-id-type="pmid">30506225</pub-id>
                    <pub-id pub-id-type="doi">10.1007/s13318-018-0534-2</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6520475</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref46">
                <label>46</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Buelga</surname>
                            <given-names>DS</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Fernandez</surname>
                            <given-names>d M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Gatta</surname>
                            <given-names>M</given-names>
                            <prefix>de</prefix>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.</article-title>
                    <source>

                        <italic toggle="yes">Antimicrob. Agents Chemother.</italic>
</source>
                    <year>2005 Dec</year>;<volume>49</volume>(<issue>12</issue>):<fpage>4934</fpage>&#x2013;<lpage>4941</lpage>.
                    <pub-id pub-id-type="pmid">16304155</pub-id>
                    <pub-id pub-id-type="doi">10.1128/AAC.49.12.4934-4941.2005</pub-id>
                    <pub-id pub-id-type="pmcid">PMC1315926</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref47">
                <label>47</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Okada</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kariya</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Irie</surname>
                            <given-names>K</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Population Pharmacokinetics of Vancomycin in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation.</article-title>
                    <source>

                        <italic toggle="yes">J. Clin. Pharmacol.</italic>
                    </source>
                    <year>2018 Sep</year>;<volume>58</volume>(<issue>9</issue>):<fpage>1140</fpage>&#x2013;<lpage>1149</lpage>. Epub 20180515.
                    <pub-id pub-id-type="pmid">29762865</pub-id>
                    <pub-id pub-id-type="doi">10.1002/jcph.1106</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref48">
                <label>48</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Tsuda</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Takahashi</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Watanabe</surname>
                            <given-names>F</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Population Pharmacokinetic Analysis of Vancomycin in Patients with Solid or Hematological Malignancy in Relation to the Quick Sequential Organ Failure Assessment Scores.</article-title>
                    <source>

                        <italic toggle="yes">Eur. J. Drug Metab. Pharmacokinet.</italic>
                    </source>
                    <year>2023 Nov</year>;<volume>48</volume>(<issue>6</issue>):<fpage>647</fpage>&#x2013;<lpage>655</lpage>. Epub 2023/09/11.
                    <pub-id pub-id-type="pmid">37695498</pub-id>
                    <pub-id pub-id-type="doi">10.1007/s13318-023-00850-8</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref49">
                <label>49</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Yellepeddi</surname>
                            <given-names>VK</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lindley</surname>
                            <given-names>B</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Radetich</surname>
                            <given-names>E</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Population pharmacokinetics and target attainment analysis of vancomycin after intermittent dosing in adults with cystic fibrosis.</article-title>
                    <source>

                        <italic toggle="yes">Antimicrob. Agents Chemother.</italic>
                    </source>
                    <year>2024 Jan 10</year>;<volume>68</volume>(<issue>1</issue>):<fpage>e0099223</fpage>. Epub 2023/12/07.
                    <pub-id pub-id-type="pmid">38059634</pub-id>
                    <pub-id pub-id-type="doi">10.1128/aac.00992-23</pub-id>
                    <pub-id pub-id-type="pmcid">PMC10777832</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref50">
                <label>50</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Medell&#x00ed;n-Garibay</surname>
                            <given-names>SE</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ortiz-Mart&#x00ed;n</surname>
                            <given-names>B</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Rueda-Naharro</surname>
                            <given-names>A</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Pharmacokinetics of vancomycin and dosing recommendations for trauma patients.</article-title>
                    <source>

                        <italic toggle="yes">J. Antimicrob. Chemother.</italic>
                    </source>
                    <year>2016 Feb</year>;<volume>71</volume>(<issue>2</issue>):<fpage>471</fpage>&#x2013;<lpage>479</lpage>. Epub 20151114.
                    <pub-id pub-id-type="pmid">26568565</pub-id>
                    <pub-id pub-id-type="doi">10.1093/jac/dkv372</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref51">
                <label>51</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Polasek</surname>
                            <given-names>TM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Shakib</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Rostami-Hodjegan</surname>
                            <given-names>A</given-names>
                        </name>
</person-group>:
                    <article-title>Precision dosing in clinical medicine: present and future.</article-title>
                    <source>

                        <italic toggle="yes">Expert Rev. Clin. Pharmacol.</italic>
</source>
                    <year>2018 Aug</year>;<volume>11</volume>(<issue>8</issue>):<fpage>743</fpage>&#x2013;<lpage>746</lpage>. Epub 2018/07/17.
                    <pub-id pub-id-type="pmid">30010447</pub-id>
                    <pub-id pub-id-type="doi">10.1080/17512433.2018.1501271</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref52">
                <label>52</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Fidler</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wilkins</surname>
                            <given-names>JJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Hooijmaijers</surname>
                            <given-names>R</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Nonlinear Mixed-Effects Model Development and Simulation Using nlmixr and Related R Open-Source Packages.</article-title>
                    <source>

                        <italic toggle="yes">CPT Pharmacometrics Syst. Pharmacol.</italic>
</source>
                    <year>2019 Sep</year>;<volume>8</volume>(<issue>9</issue>):<fpage>621</fpage>&#x2013;<lpage>633</lpage>. Epub 2019/06/18.
                    <pub-id pub-id-type="pmid">31207186</pub-id>
                    <pub-id pub-id-type="doi">10.1002/psp4.12445</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6765694</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref53">
                <label>53</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Michels</surname>
                            <given-names>WM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Grootendorst</surname>
                            <given-names>DC</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Verduijn</surname>
                            <given-names>M</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size.</article-title>
                    <source>

                        <italic toggle="yes">Clin. J. Am. Soc. Nephrol.</italic>
</source>
                    <year>2010 Jun</year>;<volume>5</volume>(<issue>6</issue>):<fpage>1003</fpage>&#x2013;<lpage>1009</lpage>. Epub 2010/03/20.
                    <pub-id pub-id-type="pmid">20299365</pub-id>
                    <pub-id pub-id-type="doi">10.2215/CJN.06870909</pub-id>
                    <pub-id pub-id-type="pmcid">PMC2879308</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref54">
                <label>54</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Grace</surname>
                            <given-names>E</given-names>
                        </name>
</person-group>:
                    <article-title>Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years.</article-title>
                    <source>

                        <italic toggle="yes">J. Antimicrob. Chemother.</italic>
                    </source>
                    <year>2012 Jun</year>;<volume>67</volume>(<issue>6</issue>):<fpage>1305</fpage>&#x2013;<lpage>1310</lpage>. Epub 2012/03/03.
                    <pub-id pub-id-type="pmid">22382471</pub-id>
                    <pub-id pub-id-type="doi">10.1093/jac/dks066</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref55">
                <label>55</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Tesfamariam</surname>
                            <given-names>NS</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Aboelezz</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Mahmoud</surname>
                            <given-names>SH</given-names>
                        </name>
</person-group>:
                    <article-title>The Impact of Augmented Renal Clearance on Vancomycin Pharmacokinetics and Pharmacodynamics in Critically Ill Patients.</article-title>
                    <source>

                        <italic toggle="yes">J. Clin. Med.</italic>
</source>
                    <year>2024</year>;<volume>13</volume>(<issue>8</issue>):<fpage>2317</fpage>.
                    <pub-id pub-id-type="pmid">38673590</pub-id>
                    <pub-id pub-id-type="doi">10.3390/jcm13082317</pub-id>
                    <pub-id pub-id-type="pmcid">PMC11051385</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref56">
                <label>56</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>He</surname>
                            <given-names>C-Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ye</surname>
                            <given-names>P-P</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Liu</surname>
                            <given-names>B</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Population Pharmacokinetics and Dosing Optimization of Vancomycin in Infants, Children, and Adolescents with Augmented Renal Clearance.</article-title>
                    <source>

                        <italic toggle="yes">Antimicrob. Agents Chemother.</italic>
</source>
                    <year>2021</year>;<volume>65</volume>(<issue>10</issue>):<fpage>e0089721</fpage>.
                    <pub-id pub-id-type="pmid">34339268</pub-id>
                    <pub-id pub-id-type="doi">10.1128/AAC.00897-21</pub-id>
                    <pub-id pub-id-type="pmcid">PMC8448120</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref57">
                <label>57</label>
                <mixed-citation publication-type="book">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Alzahrani</surname>
                            <given-names>AM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Naeem</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>AlAzmi</surname>
                            <given-names>A</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <chapter-title>Altered Pharmacokinetics Parameters of Vancomycin in Patients with Hematological Malignancy with Febrile Neutropenia, a Bayesian Software Estimation.</chapter-title>
                    <source>

                        <italic toggle="yes">Antibiotics (Basel, Switzerland).</italic>
</source>
                    <year>2023 May 29</year>;<volume>12</volume>(<issue>6</issue>). Epub 2023/06/28.
                    <pub-id pub-id-type="pmid">37370298</pub-id>
                    <pub-id pub-id-type="doi">10.3390/antibiotics12060979</pub-id>
                    <pub-id pub-id-type="pmcid">PMC10295334</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref58">
                <label>58</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Diego</surname>
                            <given-names>N</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Juan-David</surname>
                            <given-names>V</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wilson</surname>
                            <given-names>B</given-names>
                        </name>
</person-group>:
                    <article-title>Vancomycin Population Pharmacokinetic Models in Non- Critically Ill Adults Patients: a scoping review.</article-title>
                    <year>2025</year>.
                    <pub-id pub-id-type="doi">10.5281/zenodo.14876777</pub-id>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
    <sub-article article-type="reviewer-report" id="report369835">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.178348.r369835</article-id>
            <title-group>
                <article-title>Reviewer response for version 2</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Yellepeddi</surname>
                        <given-names>Venkata Kashyap</given-names>
                    </name>
                    <xref ref-type="aff" rid="r369835a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0003-3819-9054</uri>
                </contrib>
                <aff id="r369835a1">
                    <label>1</label>Spencer Fox Eccles School of Medicine, Department of Pediatrics, The University of Utah, Salt Lake City, Utah, USA</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>21</day>
                <month>3</month>
                <year>2025</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2025 Yellepeddi VK</copyright-statement>
                <copyright-year>2025</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport369835" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.128260.2"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>Authors have addressed all my comments satisfactorily.</p>
            <p>Are the rationale for, and objectives of, the Systematic Review clearly stated?</p>
            <p>Yes</p>
            <p>Is the statistical analysis and its interpretation appropriate?</p>
            <p>Not applicable</p>
            <p>If this is a Living Systematic Review, is the &#x2018;living&#x2019; method appropriate and is the search schedule clearly defined and justified? (&#x2018;Living Systematic Review&#x2019; or a variation of this term should be included in the title.)</p>
            <p>Not applicable</p>
            <p>Are sufficient details of the methods and analysis provided to allow replication by others?</p>
            <p>Yes</p>
            <p>Are the conclusions drawn adequately supported by the results presented in the review?</p>
            <p>Yes</p>
            <p>Reviewer Expertise:</p>
            <p>Clinical Pharmacology, Nanotechnology. Mode-informed drug design, Population PK modeling, Physiologically based pharmacokinetic modeling.</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.</p>
        </body>
    </sub-article>
    <sub-article article-type="reviewer-report" id="report369834">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.178348.r369834</article-id>
            <title-group>
                <article-title>Reviewer response for version 2</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Abouelkheir</surname>
                        <given-names>Manal</given-names>
                    </name>
                    <xref ref-type="aff" rid="r369834a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-6331-4443</uri>
                </contrib>
                <aff id="r369834a1">
                    <label>1</label>Misr International University, Cairo, Cairo Governorate, Egypt</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>20</day>
                <month>3</month>
                <year>2025</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2025 Abouelkheir M</copyright-statement>
                <copyright-year>2025</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport369834" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.128260.2"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>Thank you to the authors for revising the manuscript and incorporating all the requested modifications. I have no further comments.</p>
            <p>Are the rationale for, and objectives of, the Systematic Review clearly stated?</p>
            <p>Yes</p>
            <p>Is the statistical analysis and its interpretation appropriate?</p>
            <p>Partly</p>
            <p>If this is a Living Systematic Review, is the &#x2018;living&#x2019; method appropriate and is the search schedule clearly defined and justified? (&#x2018;Living Systematic Review&#x2019; or a variation of this term should be included in the title.)</p>
            <p>Not applicable</p>
            <p>Are sufficient details of the methods and analysis provided to allow replication by others?</p>
            <p>Partly</p>
            <p>Are the conclusions drawn adequately supported by the results presented in the review?</p>
            <p>Partly</p>
            <p>Reviewer Expertise:</p>
            <p>Antibiotics pharmacokinetics</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.</p>
        </body>
    </sub-article>
    <sub-article article-type="reviewer-report" id="report234168">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.140830.r234168</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Abouelkheir</surname>
                        <given-names>Manal</given-names>
                    </name>
                    <xref ref-type="aff" rid="r234168a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-6331-4443</uri>
                </contrib>
                <aff id="r234168a1">
                    <label>1</label>Misr International University, Cairo, Cairo Governorate, Egypt</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>6</day>
                <month>8</month>
                <year>2024</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2024 Abouelkheir M</copyright-statement>
                <copyright-year>2024</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport234168" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.128260.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>This scoping review is comprehensive and well-structured. It provides valuable insight into PopPK models of vancomycin in non-critically ill patients. It highlights important covariates and model parameters while pointing out the variability and limitations in existing studies. It also offers practical recommendations for future research. Below are some comments to improve the quality of the manuscript.</p>
            <p> 
                <bold>Abstract:</bold> 
                <list list-type="bullet">
                    <list-item>
                        <p>Please make the abstract more concise by summarizing the search strategy and inclusion criteria in fewer words in the method, focusing the results on the most critical findings, such as the main covariates and models used, and finally, highlighting the key takeaway points briefly in the conclusion.</p>
                    </list-item>
                </list> 
                <bold>Methods:</bold> 
                <list list-type="bullet">
                    <list-item>
                        <p>The method has two redundant sentences: &#x201c;Articles that did not meet inclusion/exclusion criteria were removed. The selected articles were reviewed by two authors (J.-D.V. and D.N.) and compared to inclusion and exclusion criteria.&#x201d; Please remove one of them.</p>
                    </list-item>
                    <list-item>
                        <p>The research question &#x201c;What is the existing evidence related to PopPK models of vancomycin in non-critical hospitalized adult patients?"&#x00a0; actually follows the PCC format (Population, Concept, Context) which is generally more appropriate than PICO for scoping reviews. The PICO format (Population, Intervention, Comparison, Outcome) is commonly used for formulating research questions in systematic reviews and clinical research, especially for randomized controlled trials. However, for scoping reviews, which aim to map the existing literature on a particular topic or research area and identify key concepts, gaps, and evidence types, the PICO format might not always be the best fit.</p>
                    </list-item>
                    <list-item>
                        <p>The authors mentioned that they included studies published between January 1980 and November 2021. But I noticed that some studies are missing, for example: Population Pharmacokinetic Model for Vancomycin Used in Open Heart Surgery: Model-Based Evaluation of Standard Dosing Regimens (
                            <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/aac.00088-18">https://doi.org/10.1128/aac.00088-18</ext-link>
                            <underline> ) </underline>and Dose Tailoring of Vancomycin Through Population Pharmacokinetic Modeling Among Surgical Patients in Pakistan (
                            <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2021.721819">https://doi.org/10.3389/fphar.2021.721819</ext-link>). In addition, more studies are published thereafter, like: Population pharmacokinetic model of vancomycin in postoperative neurosurgical patients (&#x00a0;
                            <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2022.1005791">https://doi.org/10.3389/fphar.2022.1005791</ext-link>). I suggest to either including them in the revised version or explaining the reason why you excluded such studies.</p>
                    </list-item>
                    <list-item>
                        <p>Remove the sentence &#x201c;The results were categorized and organized into subgroups in Table 2 and Table 3.&#x201d; From the method section and better refer to these tables in the results section in a more descriptive way for the content of each table.</p>
                    </list-item>
                </list> </p>
            <p> 
                <bold>Results:</bold> 
                <list list-type="bullet">
                    <list-item>
                        <p>The authors mentioned that &#x201c;after removing the duplicate studies, 134 articles remained for screening and 73 of these articles were selected for review. Finally, we considered 17 articles that met the inclusion/exclusion criteria&#x201d;. The stepwise screening approach needs further clarification. What is the difference between 1
                            <sup>st</sup> and 2
                            <sup>nd</sup> screening steps? Could you please further clarify on which base you reduced the number of studies from 134 to 73 and then to 17??</p>
                    </list-item>
                    <list-item>
                        <p>It is mentioned in the results section that &#x201c;The study populations were categorized into four groups: (a) renal, (b) obese, (c) older, and (d) cancer patients (Figure 1)&#x201d; However, Figure 1 shows the flowchart of selected studies, not the patient categorization. Please correct it.</p>
                    </list-item>
                    <list-item>
                        <p>The results section mentions that &#x201c;these results are shown in Table 2.&#x201d; A suggested better description for Table 2 would be &#x201c; A summary of demographics and PopPK modeling methods for all the included studies is presented in Table 2.&#x201d;</p>
                    </list-item>
                    <list-item>
                        <p>All abbreviations in the tables should be spelled out as a footnote under the tables.</p>
                    </list-item>
                    <list-item>
                        <p>The results section mentions that &#x201c;Only 3 studies (17.3%) had external validation (Table 3).&#x201d; However, information about validity is mentioned in Table 2, not 3.</p>
                    </list-item>
                    <list-item>
                        <p>It is mentioned in the results section &#x201c;Table 3 summarizes the results of the 17 studies&#x201d;. Actually table 3 summarizes the models formula, and parameters not the whole results of the 17 studies.&#x00a0;</p>
                    </list-item>
                    <list-item>
                        <p>&#x201c;Table 3: Characteristics PK models&#x201d; Please write a more descriptive title for Table 3.</p>
                    </list-item>
                    <list-item>
                        <p>It is mentioned that &#x201c;The lowest vancomycin CL value was reported in the study by Ma KF et al., where a typical value of 2.08 L/h was reported. For the patients in this study, a mean value of 2.08mL/min was reported for CLCR.&#x201d; The value 2.08 couldn&#x2019;t be the same for both vancomycin Cl and CLCR. I believe it is a typo for CLCR, please correct it and rephrase the sentence for better readability.</p>
                    </list-item>
                    <list-item>
                        <p>It is mentioned that &#x201c;The lowest TVV was 42 L in the subgroup of non-cancer patients in the Alqhatani study and the highest was 66.4 L in the patients with unstable and stable kidney function.7&#x201d;. Reference 7 is the updated vancomycin guideline 2020, not the study that reported this value of TVV. Also, how come the TVV of 66.4 L is the same for patients with stable and unstable kidney function? Do you mean that kidney function has no effect on TVV?</p>
                    </list-item>
                    <list-item>
                        <p>In the result section, it is mentioned that &#x201c;Although most studies with two-compartment models reported parameters in the form of flow rates (CL and Q), two studies reported model parameters in the form of elimination, transfer rate constants (k
                            <sub>10</sub>, k
                            <sub>12</sub>, k
                            <sub>21</sub>) were presented.&#x201d; Could you please spell out each abbreviation when it first appears?</p>
                    </list-item>
                    <list-item>
                        <p>In the result section, it is mentioned that &#x201c;One article used furosemide and other cystatin C for glomerular filtration rate (GFR) estimation.&#x201d; How furosemide was used for GFR estimation?</p>
                    </list-item>
                    <list-item>
                        <p>&#x201c;GFR was the main covariable that affected the models, and this covariate was used to explain between-individual variability in drug clearance.&#x201d; What about covariates to explain variability in volume of distribution&#x201d;</p>
                    </list-item>
                </list> 
                <bold>Discussion:</bold> 
                <list list-type="bullet">
                    <list-item>
                        <p>It is mentioned in the discussion section that &#x201c;Despite the multiple limitations of the Cockcroft Gault equation, most of the articles used it&#x201d;. Could you please elaborate more on the limitations of Cockcroft Gault equation.</p>
                    </list-item>
                    <list-item>
                        <p>&#x201c;In the volume parameter, we can notice that the two volumes that are above the mean are those of the geriatric patients and the general group.&#x201d; And then you referred to the Medellin Garibay article, which actually includes trauma patients who are considered a special population, not a general population.</p>
                    </list-item>
                    <list-item>
                        <p>In the discussion sections the authors commented only on the populations who have above the mean clearance and volume of distribution. Could you please also comment on populations who have below the mean parameters.</p>
                    </list-item>
                    <list-item>
                        <p>In the discussion section, &#x201c;For the obese subpopulation, the elimination rate constant (k10=CL/V) could be affected by the patients being overweight and in the geriatric subpopulation by a change in the central compartment volume. A solution to this problem would be to increase the loading dose to achieve a faster steady state and make it easier for them to achieve the target of AUC/MIC &gt; 400 to ensure an adequate bactericidal effect.&#x201d; This paragraph is a bit confusing. You already mentioned in a previous paragraph that obese patients had higher CL and geriatric had higher V, you just repeated the same information but in another word. And does the loading dose would be helpful only with obese and geriatric patients, or with other general populations?</p>
                    </list-item>
                    <list-item>
                        <p>The order of the paragraphs of the discussion section needs to be revised for better readability. The 3
                            <sup>rd</sup> and 7
                            <sup>th</sup> paragraphs talk about vancomycin elimination, renal patients, and equations to estimate renal function. I suggest combining them together. Again, the 8
                            <sup>th</sup> paragraph can be combined with the 5
                            <sup>th</sup> one when talking about cancer patients.</p>
                    </list-item>
                </list> 
                <bold>General comments:</bold>
            </p>
            <p> &#x00a0; 
                <list list-type="bullet">
                    <list-item>
                        <p>The whole manuscript needs proofreading with language and grammatical editing to improve readability.</p>
                    </list-item>
                    <list-item>
                        <p>Abbreviations should be spelled out when 1
                            <sup>st</sup> appears.</p>
                    </list-item>
                    <list-item>
                        <p>Please replace the term &#x201c;non-critical adults&#x201d; throughout the text with &#x201c;non-critical ill adults.&#x201d;.</p>
                    </list-item>
                </list>
            </p>
            <p>Are the rationale for, and objectives of, the Systematic Review clearly stated?</p>
            <p>Yes</p>
            <p>Is the statistical analysis and its interpretation appropriate?</p>
            <p>Partly</p>
            <p>If this is a Living Systematic Review, is the &#x2018;living&#x2019; method appropriate and is the search schedule clearly defined and justified? (&#x2018;Living Systematic Review&#x2019; or a variation of this term should be included in the title.)</p>
            <p>Not applicable</p>
            <p>Are sufficient details of the methods and analysis provided to allow replication by others?</p>
            <p>Partly</p>
            <p>Are the conclusions drawn adequately supported by the results presented in the review?</p>
            <p>Partly</p>
            <p>Reviewer Expertise:</p>
            <p>Antibiotics pharmacokinetics</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p>
        </body>
        <sub-article article-type="response" id="comment13362-234168">
            <front-stub>
                <contrib-group>
                    <contrib contrib-type="author">
                        <name>
                            <surname>Bustos</surname>
                            <given-names>Rosa Helena</given-names>
                        </name>
                        <aff>Universidad de La Sabana, Colombia</aff>
                    </contrib>
                </contrib-group>
                <author-notes>
                    <fn fn-type="conflict">
                        <p>
                            <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                    </fn>
                </author-notes>
                <pub-date pub-type="epub">
                    <day>16</day>
                    <month>2</month>
                    <year>2025</year>
                </pub-date>
            </front-stub>
            <body>
                <p>Original comments of the reviewer</p>
                <p> Reply by the author(s)</p>
                <p> Changes done on page number and line number</p>
                <p> </p>
                <p> This scoping review is comprehensive and well-structured. It provides valuable insight into PopPK models of vancomycin in non-critically ill patients. It highlights important covariates and model parameters while pointing out the variability and limitations in existing studies. It also offers practical recommendations for future research. Below are some comments to improve the quality of the manuscript.</p>
                <p> </p>
                <p> We would like to thank the reviewer for the painstaking review of our document and the suggestions made. We have taken the suggestions to heart and made the appropriate corrections and revision which have thereby strengthened and enriched our manuscript</p>
                <p> </p>
                <p> 
                    <bold>Abstract</bold>
                </p>
                <p> </p>
                <p> 1&#x00a0;Please make the abstract more concise by summarizing the search strategy and inclusion criteria in fewer words in the method, focusing the results on the most critical findings, such as the main covariates and models used, and finally, highlighting the key takeaway points briefly in the conclusion.</p>
                <p> </p>
                <p> 
                    <bold>Answer: </bold>The abstract has been revised and modified, with an emphasis on focusing the results on the most critical findings, such as the main covariates and models used. Key aspects of the study have been highlighted in the conclusion.</p>
                <p> Page 1</p>
                <p> Line 11-27</p>
                <p> </p>
                <p> 
                    <bold>Methods</bold>
                </p>
                <p> </p>
                <p> 2&#x00a0;The method has two redundant sentences: &#x201c;Articles that did not meet inclusion/exclusion criteria were removed. The selected articles were reviewed by two authors (J.-D.V. and D.N.) and compared to inclusion and exclusion criteria.&#x201d; Please remove one of them.</p>
                <p> </p>
                <p> 
                    <bold>Answer:&#x00a0;</bold>The methods section has been thoroughly revised and modified.</p>
                <p> Page 2</p>
                <p> Line 66-85</p>
                <p> </p>
                <p> 3&#x00a0;The research question &#x201c;What is the existing evidence related to PopPK models of vancomycin in non-critical hospitalized adult patients?"&#x00a0; actually follows the PCC format (Population, Concept, Context) which is generally more appropriate than PICO for scoping reviews. The PICO format (Population, Intervention, Comparison, Outcome) is commonly used for formulating research questions in systematic reviews and clinical research, especially for randomized controlled trials. However, for scoping reviews, which aim to map the existing literature on a particular topic or research area and identify key concepts, gaps, and evidence types, the PICO format might not always be the best fit.</p>
                <p> </p>
                <p> 
                    <bold>Answer:&#x00a0;</bold>The reviewer&#x2019;s observation is absolutely valid. The methods section has been thoroughly revised and updated."</p>
                <p> Page 2</p>
                <p> Line 71-73</p>
                <p> </p>
                <p> 4&#x00a0;The authors mentioned that they included studies published between January 1980 and November 2021. But I noticed that some studies are missing, for example: Population Pharmacokinetic Model for Vancomycin Used in Open Heart Surgery: Model-Based Evaluation of Standard Dosing Regimens (https://doi.org/10.1128/aac.00088-18 ) and Dose Tailoring of Vancomycin Through Population Pharmacokinetic Modeling Among Surgical Patients in Pakistan (https://doi.org/10.3389/fphar.2021.721819). In addition, more studies are published thereafter, like: Population pharmacokinetic model of vancomycin in postoperative neurosurgical patients ( https://doi.org/10.3389/fphar.2022.1005791). I suggest to either including them in the revised version or explaining the reason why you excluded such studies.</p>
                <p> </p>
                <p> 
                    <bold>Answer:&#x00a0;</bold>A new literature search has been ongoing as of November 2024, leading to an increase in the number of included articles from 17 in the initial review to 36 in this revised version submitted to the reviewers. The analysis of these studies has been presented in Tables 2 and 3. Additionally, the articles suggested by the reviewer have been incorporated into the updated literature search</p>
                <p> Page 2&#x00a0;Line 76-79</p>
                <p> Table 2, Page 6-9</p>
                <p> Table 3, Page 10-13</p>
                <p> </p>
                <p> 5&#x00a0;Remove the sentence &#x201c;The results were categorized and organized into subgroups in Table 2 and Table 3.&#x201d; From the method section and better refer to these tables in the results section in a more descriptive way for the content of each table.</p>
                <p> </p>
                <p> 
                    <bold>Answer:&#x00a0;</bold>The results section has been completely revised. The findings from the newly included articles in Tables 2 and 3 have been incorporated, and their description has been presented in this section.</p>
                <p> Table 2, Page 6-9</p>
                <p> Table 3, Page 10-13</p>
                <p> Page 3 Line 92-96</p>
                <p> Page 3 Line 122-141</p>
                <p> Page 4 Line 142-145</p>
                <p> </p>
                <p> 
                    <bold>Results</bold>
                </p>
                <p> </p>
                <p> 6&#x00a0;The authors mentioned that &#x201c;after removing the duplicate studies, 134 articles remained for screening and 73 of these articles were selected for review. Finally, we considered 17 articles that met the inclusion/exclusion criteria&#x201d;. The stepwise screening approach needs further clarification. What is the difference between 1st and 2nd screening steps? Could you please further clarify on which base you reduced the number of studies from 134 to 73 and then to 17??</p>
                <p> </p>
                <p> 
                    <bold>Answer:&#x00a0;</bold>The study flowchart has been modified to include the newly selected studies. The description of identification, screening, and inclusion has been carefully reviewed.</p>
                <p> Figure 1 -Page 3</p>
                <p> </p>
                <p> 7&#x00a0;It is mentioned in the results section that &#x201c;The study populations were categorized into four groups: (a) renal, (b) obese, (c) older, and (d) cancer patients (Figure 1)&#x201d; However, Figure 1 shows the flowchart of selected studies, not the patient categorization. Please correct it.</p>
                <p> </p>
                <p> 
                    <bold>Answer:&#x00a0;</bold>The flowchart has been revised and updated to include the newly identified studies from the expanded search. However, Figure 1 does not display the categorization of the groups. The description of the categorization has been included in the results section.</p>
                <p> Page 2</p>
                <p> Line 122-125</p>
                <p> </p>
                <p> 8&#x00a0;The results section mentions that &#x201c;these results are shown in Table 2.&#x201d; A suggested better description for Table 2 would be &#x201c; A summary of demographics and PopPK modeling methods for all the included studies is presented in Table 2.&#x201d;</p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold> The description of Table 2, as suggested by the reviewer, has been included in the text.</p>
                <p> Page 4&#x00a0;Line 144-145</p>
                <p> </p>
                <p> 9&#x00a0;All abbreviations in the tables should be spelled out as a footnote under the tables.</p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold>&#x00a0;The abbreviations in the table have been spelled out under the tables.</p>
                <p> Table 2 Page 9</p>
                <p> Table 3 Page 13</p>
                <p> </p>
                <p> </p>
                <p> 10&#x00a0;The results section mentions that &#x201c;Only 3 studies (17.3%) had external validation (Table 3).&#x201d; However, information about validity is mentioned in Table 2, not 3.</p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold>&#x00a0;The results section has been revised and modified according to the reviewer&#x2019;s suggestion</p>
                <p> Page 3 Line 92-96</p>
                <p> Page 3 Line 122-141</p>
                <p> Page 4 Line 142-145</p>
                <p> </p>
                <p> 11&#x00a0;It is mentioned in the results section &#x201c;Table 3 summarizes the results of the 17 studies&#x201d;. Actually table 3 summarizes the models formula, and parameters not the whole results of the 17 studies.</p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold>&#x00a0;The number of included articles has increased from 17 in the initial review to 36 in this revised version, which has been submitted to the reviewers. All 36 studies have been included in Tables 2 and 3.&#x00a0;
                    <italic>Note: The study by Alqahtani et al. (2020) has been included in two categories: General and Cancer.</italic>
                </p>
                <p> Table 2, Page 6-9</p>
                <p> Table 3, Page 10-13</p>
                <p> </p>
                <p> </p>
                <p> 12&#x00a0;&#x201c;Table 3: Characteristics PK models&#x201d; Please write a more descriptive title for Table 3.</p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold>&#x00a0;The name of table 3 has been modified.</p>
                <p> Table 3 Page 10</p>
                <p> </p>
                <p> 13&#x00a0;It is mentioned that &#x201c;The lowest vancomycin CL value was reported in the study by Ma KF et al., where a typical value of 2.08 L/h was reported. For the patients in this study, a mean value of 2.08mL/min was reported for CLCR.&#x201d; The value 2.08 couldn&#x2019;t be the same for both vancomycin Cl and CLCR. I believe it is a typo for CLCR, please correct it and rephrase the sentence for better readability.</p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold>&#x00a0;The results section has been completely modified due to the increased number of studies included in the paper. However, after reviewing the reviewer's suggestion, the value of 2.08 L/h was confirmed to correspond to the CL value, as presented in Table 3.</p>
                <p> Result section</p>
                <p> Table 3 Page 10-13</p>
                <p> </p>
                <p> 14&#x00a0;It is mentioned that &#x201c;The lowest TVV was 42 L in the subgroup of non-cancer patients in the Alqhatani study and the highest was 66.4 L in the patients with unstable and stable kidney function.7&#x201d;. Reference 7 is the updated vancomycin guideline 2020, not the study that reported this value of TVV. Also, how come the TVV of 66.4 L is the same for patients with stable and unstable kidney function? Do you mean that kidney function has no effect on TVV?</p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold>&#x00a0;&#x00a0;The TVV values have been reviewed. The description of the TVV values for each category has been modified according to the newly included studies.</p>
                <p> Page 5</p>
                <p> Line 202-208</p>
                <p> </p>
                <p> 15&#x00a0;In the result section, it is mentioned that &#x201c;Although most studies with two-compartment models reported parameters in the form of flow rates (CL and Q), two studies reported model parameters in the form of elimination, transfer rate constants (k10, k12, k21) were presented.&#x201d; Could you please spell out each abbreviation when it first appears?</p>
                <p> </p>
                <p> 
                    <bold>Answer:&#x00a0;</bold>The abbreviations have been reviewed throughout the text and spelled out upon their first appearance.</p>
                <p> All document</p>
                <p> </p>
                <p> 16&#x00a0;In the result section, it is mentioned that &#x201c;One article used furosemide and other cystatin C for glomerular filtration rate (GFR) estimation.&#x201d; How furosemide was used for GFR estimation?</p>
                <p> The paragraph has been revised and modified.</p>
                <p> </p>
                <p> 
                    <bold>Answer: </bold>Furosemide was not directly used to estimate the glomerular filtration rate (GFR). Instead, it was administered as part of a furosemide stress test, which has been proposed as a functional marker of renal reserve. This test assesses renal response to a standardized dose of furosemide and has been used to predict acute kidney injury (AKI) progression in critically ill patients. However, in the context of the referenced study, cystatin C was the primary biomarker used for GFR estimation.</p>
                <p> Page 4</p>
                <p> Line 162-167</p>
                <p> </p>
                <p> 17&#x00a0;&#x201c;GFR was the main covariable that affected the models, and this covariate was used to explain between-individual variability in drug clearance.&#x201d; What about covariates to explain variability in volume of distribution&#x201d;</p>
                <p> The paragraph has been revised and modified.</p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold> In our analysis, variability in the volume of distribution (Vd) was primarily assessed in relation to physiological and clinical covariates. While GFR significantly influenced drug clearance, other factors such as body weight, age, and serum albumin levels were evaluated as potential covariates for Vd. Among these, body weight showed the strongest correlation with Vd, which is consistent with its role in determining drug distribution, particularly for hydrophilic compounds like vancomycin.</p>
                <p> </p>
                <p> Table 3</p>
                <p> Pag 10-13</p>
                <p> </p>
                <p> 
                    <bold>Discussion</bold>
                </p>
                <p> </p>
                <p> 18&#x00a0;It is mentioned in the discussion section that &#x201c;Despite the multiple limitations of the Cockcroft Gault equation, most of the articles used it&#x201d;. Could you please elaborate more on the limitations of Cockcroft Gault equation.</p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold>&#x00a0;A paragraph in the discussion section has been added.</p>
                <p> The Cockcroft-Gault equation, despite its widespread use in pharmacokinetic studies and drug dosing adjustments, has several limitations. It was developed in a specific population, primarily adult males, which limits its applicability to other groups such as elderly individuals, patients with altered body composition (e.g., obesity, cachexia), or critically ill patients. Additionally, since it relies on serum creatinine levels, it is influenced by factors such as muscle mass, diet, and hydration status, potentially leading to inaccurate estimations of renal function. The equation also lacks standardization across different creatinine assay methods, and its accuracy diminishes in patients with very low or highly fluctuating glomerular filtration rates (GFR), such as those with acute kidney injury (AKI). Moreover, the use of actual body weight can introduce further errors, particularly in patients with obesity or fluid overload. Despite these limitations, Cockcroft-Gault remains widely used due to its historical application in drug dosing guidelines and its inclusion in many pharmacokinetic models.</p>
                <p> Page 14</p>
                <p> Line 271-281</p>
                <p> </p>
                <p> 19&#x00a0;&#x201c;In the volume parameter, we can notice that the two volumes that are above the mean are those of the geriatric patients and the general group.&#x201d; And then you referred to the Medellin Garibay article, which actually includes trauma patients who are considered a special population, not a general population.</p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold> We acknowledge the inconsistency in our statement regarding the classification of the population in the Medell&#x00ed;n-Garibay study. While we initially referred to it as a "general group," we recognize that this study specifically includes trauma patients, who are considered a special population due to their distinct physiological and pharmacokinetic characteristics. The paragraph has been revised and modified.</p>
                <p> </p>
                <p> Table 2 and Table 3</p>
                <p> </p>
                <p> 20&#x00a0;In the discussion sections the authors commented only on the populations who have above the mean clearance and volume of distribution. Could you please also comment on populations who have below the mean parameters.</p>
                <p> </p>
                <p> 
                    <bold>Answer:&#x00a0;</bold>The discussion section has been revised and a new paragraph added according to the reviewer's suggestion.</p>
                <p> </p>
                <p> Patients with above-the-mean vancomycin clearance and volume of distribution typically exhibit pharmacokinetic profiles associated with increased drug elimination and expanded drug distribution. Several factors may contribute to these elevated parameters, including younger age, preserved or augmented renal function, higher body weight, and conditions associated with hyperdynamic circulation, such as sepsis or burns. Higher clearance rates may result in subtherapeutic vancomycin concentrations, potentially reducing efficacy and increasing the risk of treatment failure, particularly in infections caused by less susceptible pathogens. Similarly, an increased volume of distribution may lead to lower peak concentrations, which could impact the drug&#x2019;s time-dependent antibacterial activity. Given these considerations, patients with above-the-mean clearance and volume of distribution may require individualized dosing strategies, such as higher initial doses, more frequent administration, or therapeutic drug monitoring to ensure optimal target attainment while minimizing the risk of underexposure.</p>
                <p> Page 15</p>
                <p> Line 303-313</p>
                <p> </p>
                <p> 21&#x00a0;In the discussion section, &#x201c;For the obese subpopulation, the elimination rate constant (k10=CL/V) could be affected by the patients being overweight and in the geriatric subpopulation by a change in the central compartment volume. A solution to this problem would be to increase the loading dose to achieve a faster steady state and make it easier for them to achieve the target of AUC/MIC &gt; 400 to ensure an adequate bactericidal effect.&#x201d; This paragraph is a bit confusing. You already mentioned in a previous paragraph that obese patients had higher CL and geriatric had higher V, you just repeated the same information but in another word. And does the loading dose would be helpful only with obese and geriatric patients, or with other general populations?</p>
                <p> </p>
                <p> 
                    <bold>Answer</bold>:&#x00a0;The order of the paragraphs of the discussion section needs to be revised for better readability. The 3rd and 7th paragraphs talk about vancomycin elimination, renal patients, and equations to estimate renal function. I suggest combining them together. Again, the 8th paragraph can be combined with the 5th one when talking about cancer patients.</p>
                <p> Due to changes in the discussion section following the inclusion of new studies, we are unable to merge these paragraphs. However, a new paragraph has been written in the discussion section specifically addressing the findings related to elimination.</p>
                <p> Pag 14-15</p>
                <p> Line 287-303</p>
                <p> </p>
                <p> 
                    <bold>General comments</bold>
                </p>
                <p> </p>
                <p> 21&#x00a0;The whole manuscript needs proofreading with language and grammatical editing to improve readability.</p>
                <p> </p>
                <p> 
                    <bold>Answer:&#x00a0;</bold>The manuscript has been fully reviewed, focusing on language and grammatical editing to enhance readability and ensure clarity, coherence, and precision in the text.</p>
                <p> All document</p>
                <p> </p>
                <p> 22&#x00a0;Abbreviations should be spelled out when 1st appears.</p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold>&#x00a0;The abbreviations have been reviewed throughout the text and spelled out upon their first appearance.</p>
                <p> All document</p>
                <p> </p>
                <p> 23&#x00a0;Please replace the term &#x201c;non-critical adults&#x201d; throughout the text with &#x201c;non-critical ill adults.&#x201d;.</p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold>&#x00a0;The entire document has been reviewed, and the term "non-critical adults" has been included</p>
                <p> All document</p>
            </body>
        </sub-article>
    </sub-article>
    <sub-article article-type="reviewer-report" id="report283849">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.140830.r283849</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Yellepeddi</surname>
                        <given-names>Venkata Kashyap</given-names>
                    </name>
                    <xref ref-type="aff" rid="r283849a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0003-3819-9054</uri>
                </contrib>
                <aff id="r283849a1">
                    <label>1</label>Spencer Fox Eccles School of Medicine, Department of Pediatrics, The University of Utah, Salt Lake City, Utah, USA</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>18</day>
                <month>7</month>
                <year>2024</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2024 Yellepeddi VK</copyright-statement>
                <copyright-year>2024</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport283849" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.128260.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>The manuscript reports the scoping review of the PoPK models of vancomycin. The review includes details about model information, covariates assessed, and PK parameters reported. Below are some of the comments that would improve the quality of this scoping review:</p>
            <p> </p>
            <p> 1. In the introduction, paragraph 2 must be rewritten. In its current form, its incoherent and incomplete. Please add more details with citations about the importance of PoPK modeling in finding optimal drug dosing regimens for narrow therapeutic index drugs.&#x00a0;&#x00a0;The sentence "Sex had no influence</p>
            <p> in the variability of PK parameters" is totally out of place remove it.</p>
            <p> 2. Please add the details of Rayyan software, such as manufacturer and country of origin.</p>
            <p> 3. Please extend the search to the year 2024 and update the current list with new articles.</p>
            <p>Are the rationale for, and objectives of, the Systematic Review clearly stated?</p>
            <p>Yes</p>
            <p>Is the statistical analysis and its interpretation appropriate?</p>
            <p>Not applicable</p>
            <p>If this is a Living Systematic Review, is the &#x2018;living&#x2019; method appropriate and is the search schedule clearly defined and justified? (&#x2018;Living Systematic Review&#x2019; or a variation of this term should be included in the title.)</p>
            <p>Not applicable</p>
            <p>Are sufficient details of the methods and analysis provided to allow replication by others?</p>
            <p>Yes</p>
            <p>Are the conclusions drawn adequately supported by the results presented in the review?</p>
            <p>Yes</p>
            <p>Reviewer Expertise:</p>
            <p>Clinical Pharmacology, Nanotechnology. Mode-informed drug design, Population PK modeling, Physiologically based pharmacokinetic modeling.</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p>
        </body>
        <sub-article article-type="response" id="comment13361-283849">
            <front-stub>
                <contrib-group>
                    <contrib contrib-type="author">
                        <name>
                            <surname>Bustos</surname>
                            <given-names>Rosa Helena</given-names>
                        </name>
                        <aff>Universidad de La Sabana, Colombia</aff>
                    </contrib>
                </contrib-group>
                <author-notes>
                    <fn fn-type="conflict">
                        <p>
                            <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                    </fn>
                </author-notes>
                <pub-date pub-type="epub">
                    <day>16</day>
                    <month>2</month>
                    <year>2025</year>
                </pub-date>
            </front-stub>
            <body>
                <p>We would like to thank the reviewer for the painstaking review of our document and the suggestions made. We have taken the suggestions to heart and made the appropriate corrections and revision which have thereby strengthened and enriched our manuscript</p>
                <p> </p>
                <p> 
                    <bold>1&#x00a0;In the introduction, paragraph 2 must be rewritten. In its current form, its incoherent and incomplete. Please add more details with citations about the importance of PoPK modeling in finding optimal drug dosing regimens for narrow therapeutic index drugs.&#x00a0;The sentence "Sex had no influence.</bold>
                </p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold> The entire introduction has been revised and updated. The reviewer&#x2019;s suggestions have been incorporated, with greater emphasis placed on the importance of PopPK modeling in optimizing drug dosing regimens for narrow therapeutic index drugs</p>
                <p> Page 1</p>
                <p> Line 47-53</p>
                <p> </p>
                <p> 
                    <bold>2&#x00a0;Please add the details of Rayyan software, such as manufacturer and country of origin.</bold>
                </p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold>&#x00a0;The details of Rayyan have been included.</p>
                <p> Page 2</p>
                <p> Line 80-83</p>
                <p> </p>
                <p> 
                    <bold>3&#x00a0;Please extend the search to the year 2024 and update the current list with new articles.</bold>
                </p>
                <p> </p>
                <p> 
                    <bold>Answer:</bold> A new literature search was conducted as of November 2024. The number of included articles has increased from 17 in the initial review to 36 in this revised version, which has been submitted to the reviewers. Tables 1 and 2 present the analysis of these studies.</p>
                <p> Page 2</p>
                <p> Line 76-79</p>
                <p> Table 2, Page 6-9</p>
                <p> Table 3, Page 10-13</p>
            </body>
        </sub-article>
    </sub-article>
</article>
